<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006539.pub4" GROUP_ID="EYES" ID="909005021509501968" MERGED_FROM="" MODIFIED="2017-01-17 17:07:24 +0000" MODIFIED_BY="Anupa Shah" REVIEW_NO="DASE01" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2017-01-17 17:07:21 +0000" MODIFIED_BY="Anupa Shah">
<TITLE MODIFIED="2009-12-08 11:30:38 +0000" MODIFIED_BY="Anupa Shah">Neuroprotection for treatment of glaucoma in adults</TITLE>
<CONTACT MODIFIED="2017-01-17 17:07:21 +0000" MODIFIED_BY="Anupa Shah"><PERSON ID="A65BCFB382E26AA2014A559401889A96" ROLE="AUTHOR"><FIRST_NAME>Dayse</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Sena</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><EMAIL_1>sena.dayse@gmail.com</EMAIL_1><MOBILE_PHONE>617-955-9571</MOBILE_PHONE><ADDRESS><ORGANISATION>Massachusetts Eye and Ear Infirmary</ORGANISATION><ADDRESS_1>243 Charles St, Connecting Building 703</ADDRESS_1><CITY>Boston</CITY><ZIP>02114</ZIP><REGION>Massachusetts</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>6179559571</PHONE_1><PHONE_2>6179559571</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-01-17 17:07:21 +0000" MODIFIED_BY="Anupa Shah"><PERSON ID="A65BCFB382E26AA2014A559401889A96" ROLE="AUTHOR"><FIRST_NAME>Dayse</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Sena</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><EMAIL_1>sena.dayse@gmail.com</EMAIL_1><MOBILE_PHONE>617-955-9571</MOBILE_PHONE><ADDRESS><ORGANISATION>Massachusetts Eye and Ear Infirmary</ORGANISATION><ADDRESS_1>243 Charles St, Connecting Building 703</ADDRESS_1><CITY>Boston</CITY><ZIP>02114</ZIP><REGION>Massachusetts</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>6179559571</PHONE_1><PHONE_2>6179559571</PHONE_2></ADDRESS></PERSON><PERSON ID="9501BF6E82E26AA20020E746E9A900D1" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Kristina</FIRST_NAME><LAST_NAME>Lindsley</LAST_NAME><POSITION>Project Director, CEVG US Project</POSITION><EMAIL_1>klindsley@jhu.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Epidemiology</DEPARTMENT><ORGANISATION>Johns Hopkins Bloomberg School of Public Health</ORGANISATION><ADDRESS_1>615 North Wolfe Street, Mail Room E6132</ADDRESS_1><CITY>Baltimore</CITY><ZIP>21205</ZIP><REGION>Maryland</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 410 502 8986</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-11-30 20:21:19 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="16" MONTH="8" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="8" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="16" MONTH="8" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-01-17 17:01:15 +0000" MODIFIED_BY="Anupa Shah">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-01-17 17:00:16 +0000" MODIFIED_BY="Anupa Shah">
<DATE DAY="17" MONTH="1" YEAR="2017"/>
<DESCRIPTION>
<P>Issue 1, 2017: No new trials identified</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-01-17 17:01:15 +0000" MODIFIED_BY="Anupa Shah">
<DATE DAY="17" MONTH="1" YEAR="2017"/>
<DESCRIPTION>
<P>Issue 1, 2017: Updated searches conducted</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-01-13 08:42:50 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-01-13 08:42:33 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Issue 2, 2013: Updated searches conducted; one new trial met the inclusion criteria and has been added (<LINK REF="STD-LoGTS-2011" TYPE="STUDY">LoGTS 2011</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-01-13 08:42:50 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Issue 2, 2013: The Abstract, Plain Language Summary, Results, Discussion, and Authors' Conclusions have all been updated accordingly.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-01-04 14:40:21 +0000" MODIFIED_BY="Anupa Shah">
<DATE DAY="23" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2017-01-17 17:04:21 +0000" MODIFIED_BY="Anupa Shah">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2017-01-17 17:04:21 +0000" MODIFIED_BY="Anupa Shah">
<SOURCE MODIFIED="2016-11-30 20:36:04 +0000" MODIFIED_BY="[Empty name]">
<NAME>Grant 1 U01 EY020522, National Eye Institute, National Institutes of Health</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2017-01-17 17:04:21 +0000" MODIFIED_BY="Anupa Shah">
<NAME>National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<UL>
<LI>Richard Wormald, Co-ordinating Editor for Cochrane Eyes and Vision (CEV) acknowledges financial support for his CEV research sessions from the Department of Health through the award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology.</LI>
<LI>The NIHR also funds the CEV Editorial Base in London.</LI>
</UL>
<P>The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS, or the Department of Health.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-01-17 17:05:47 +0000" MODIFIED_BY="Anupa Shah">
<SUMMARY MODIFIED="2017-01-17 17:02:37 +0000" MODIFIED_BY="Anupa Shah">
<TITLE MODIFIED="2017-01-16 17:33:07 +0000" MODIFIED_BY="[Empty name]">Neuroprotection (medicines to protect nerves involved in sight) for treatment of glaucoma in adults</TITLE>
<SUMMARY_BODY MODIFIED="2017-01-17 17:02:37 +0000" MODIFIED_BY="Anupa Shah">
<P>
<B>Review aim</B>
<BR/>The aim of this Cochrane review was to find out if neuroprotective medications (which aim to protect the nerves and cells in the eye) are effective for treating glaucoma in adults. We searched for all relevant studies to answer this question and found one study.</P>
<P>
<B>Key messages</B>
<BR/>Neuroprotective glaucoma medications aim to prevent vision loss in eyes with glaucoma. However, at present there is not enough evidence to show if these medicines are effective treatments for glaucoma or protect nerves and cells in the eyes directly.</P>
<P>
<B>What was studied in this review?</B>
<BR/>Glaucoma is a leading cause of blindness worldwide. The disease leads to damage of the optic nerve that worsens over time. Furthermore, cells in the retina that send messages to the optic nerve (retinal ganglion cells) become damaged and die off. This affects normal sight in the areas of the middle, sides, or top and bottom of a person&#8217;s view (loss of visual field).</P>
<P>Medicines exist that might protect the optic nerve from damage and prevent the death of retinal ganglion cells in people with glaucoma. Neuroprotective medication(s) are prescribed for glaucoma with the goal of preventing or slowing vision loss by protecting the optic nerve.</P>
<P>
<B>Key results</B>
<BR/>We searched multiple electronic databases for studies and found one study that compared two different eyedrop treatments, given to two groups of adults with low-pressure glaucoma. One group received brimonidine, a neuroprotective drug. The other group received timolol, a drug that lowers fluid pressure in the eyes. The study investigators followed these two groups of people for four years to see if either treatment protected the optic nerve and prevented vision loss.</P>
<P>The study began with 99 people in the brimonidine group and 79 people in the timolol group. After four years, many of the people had dropped out of the study: only 45 people (45%) remained in the brimonidine group and 56 (70%) people in the timolol group. As so many people dropped out, and more people who left the study were taking brimonidine than were taking timolol, it was difficult to interpret the results of the study. Bearing this in mind, after four years of treatment, people in the brimonidine group had kept more of their vision (40/45 or 88%) than those in the timolol group (38/56 or 67%). We do not know the results for the people who dropped out of the study.</P>
<P>Neither group showed any important change in eye pressure (intraocular pressure). Information about visual sharpness (visual acuity) was reported sufficiently for analysis. No information about vertical cup-disc ratio (a measure of potential optic nerve damage), quality of life or economic outcome was reported. The most common side effect was an allergic reaction to the medicines in the eye, which affected 20/99 (20%) people in the brimonidine group and 3/79 (4%) people in the timolol group.</P>
<P>
<B>How up-to-date is this review?</B>
<BR/>We searched for studies published up to 16 August 2016.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-01-17 17:05:37 +0000" MODIFIED_BY="Anupa Shah">
<ABS_BACKGROUND MODIFIED="2017-01-11 22:40:26 +0000" MODIFIED_BY="[Empty name]">
<P>Glaucoma is a heterogeneous group of conditions involving progressive damage to the optic nerve, deterioration of retinal ganglion cells, and ultimately visual field loss. It is a leading cause of blindness worldwide. Open angle glaucoma (OAG), the most common form of glaucoma, is a chronic condition that may or may not present with increased intraocular pressure (IOP). Neuroprotection for glaucoma refers to any intervention intended to prevent optic nerve damage or cell death.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2017-01-11 22:41:19 +0000" MODIFIED_BY="[Empty name]">
<P>The objective of this review was to systematically examine the evidence regarding the effectiveness of neuroprotective agents for slowing the progression of OAG in adults compared with no neuroprotective agent, placebo, or other glaucoma treatment.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-01-11 22:43:29 +0000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 7), Ovid MEDLINE, Epub Ahead of Print, In-Process &amp; Other Non-Indexed Citations, Ovid MEDLINE Daily (January 1946 to August 2016), Embase (January 1980 to August 2016), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to August 2016), the ISRCTN registry (<A HREF="http://www.isrctn.com/editAdvancedSearch">www.isrctn.com/editAdvancedSearch</A>), ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://www.who.int/ictrp/search/en">www.who.int/ictrp/search/en</A>). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 16 August 2016.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2017-01-17 17:05:37 +0000" MODIFIED_BY="Anupa Shah">
<P>We included randomised controlled trials (RCTs) in which topical or oral treatments were used for neuroprotection in adults with OAG. Minimum follow-up time was four years.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-01-11 22:46:04 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently reviewed titles and abstracts from the literature searches. We obtained full-text copies of potentially relevant studies and re-evaluated for inclusion. Two review authors independently extracted data related to study characteristics, risk of bias, and outcomes. We identified one trial for this review, thus we performed no meta-analysis. Two studies comparing memantine to placebo are currently awaiting classification until study investigators provide additional study details. We documented reasons for excluding studies from the review.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-01-16 17:42:18 +0000" MODIFIED_BY="[Empty name]">
<P>We included one multicenter RCT of adults with low-pressure glaucoma (Low-pressure Glaucoma Treatment Study, LoGTS) conducted in the USA. The primary outcome was progression of visual field loss after four years of treatment with either brimonidine or timolol. Of the 190 adults enrolled in the study, the investigators excluded 12 (6.3%) after randomization; 77 participants (40.5%) did not complete four years of follow-up. The rate of attrition was unbalanced between groups with more participants dropping out of the brimonidine group (55%) than the timolol group (29%).</P>
<P>Of those remaining in the study at four years, participants assigned to brimonidine showed less progression of visual field loss than participants assigned to timolol (risk ratio (RR) 0.35, 95% confidence interval (CI) 0.14 to 0.86; 101 participants). Because of high risk of attrition bias and potential selective outcome reporting, we graded the certainty of evidence for this outcome as very low. At the four-year follow-up, the mean IOP was similar in both groups among those for whom data were available (mean difference 0.20 mmHg, 95% CI -0.73 to 1.13; 91 participants; very low-certainty evidence). The study authors did not report analyzable data for visual acuity or any data related to vertical cup-disc ratio, quality of life, or economic outcomes. The most frequent adverse event was ocular allergy to the study drug, which affected more participants in the brimonidine group than the timolol group (RR 5.32, 95% CI 1.64 to 17.26; 178 participants; very low-certainty evidence).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-01-11 23:03:33 +0000" MODIFIED_BY="[Empty name]">
<P>Although the only trial we included in this review found less visual field loss in the brimonidine-treated group, the evidence was of such low certainty that we can draw no conclusions from this finding. Further clinical research is needed to determine whether neuroprotective agents may be beneficial for individuals with OAG. Such research should focus on outcomes important to patients, such as preservation of vision, and how these outcomes relate to cell death and optic nerve damage. As OAG is a chronic, progressive disease with variability in symptoms, RCTs designed to measure the effectiveness of neuroprotective agents require a long-term follow-up of five years or longer to detect clinically meaningful effects.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-01-17 17:05:47 +0000" MODIFIED_BY="Anupa Shah">
<BACKGROUND MODIFIED="2017-01-13 09:03:41 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2017-01-13 09:00:18 +0000" MODIFIED_BY="[Empty name]">
<P>Glaucoma is part of a heterogeneous group of conditions with multiple etiologies (causes). It is characterized by optic neuropathies that involve structural damage of the optic nerve, death of retinal ganglion cells (RGCs), and defects of the visual field. The optic nerve, formed by the clustering of axons from RGCs located in the ganglion cell layer of the retina, carries visual impulses from the eye to the brain (<LINK REF="REF-Gupta-1997" TYPE="REFERENCE">Gupta 1997</LINK>). When optic nerve damage or deterioration causes the transfer of information to be disrupted, vision loss occurs.</P>
<P>There are two main categories of primary glaucoma: open angle glaucoma and closed angle glaucoma. Open angle glaucoma (OAG), the most common form of glaucoma, is a chronic and progressive optic nerve disease that is likely to be affected by multiple genetic and environmental factors (<LINK REF="REF-Fan-2010" TYPE="REFERENCE">Fan 2010</LINK>; <LINK REF="REF-Hauser-2006a" TYPE="REFERENCE">Hauser 2006a</LINK>; <LINK REF="REF-Hauser-2006b" TYPE="REFERENCE">Hauser 2006b</LINK>). Open angle glaucoma may be accompanied by increased intraocular pressure (IOP) (pressure inside the eye), as with primary open angle glaucoma (POAG), or normal IOP, as with normal-tension glaucoma. Closed angle glaucoma tends to occur suddenly and is beyond the scope of this review.</P>
<SUBSECTION>
<HEADING LEVEL="3">Epidemiology</HEADING>
<P>Glaucoma is the second-leading cause of vision loss in the world (<LINK REF="REF-Quigley-2006" TYPE="REFERENCE">Quigley 2006</LINK>; <LINK REF="REF-Resnikoff-2004" TYPE="REFERENCE">Resnikoff 2004</LINK>), and an increasingly important public health concern due to the aging world population. The World Health Organization estimates that 105 million people have glaucoma worldwide, and around 5 million are blind as a consequence (<LINK REF="REF-Osborne-2003" TYPE="REFERENCE">Osborne 2003</LINK>; <LINK REF="REF-Quigley-2006" TYPE="REFERENCE">Quigley 2006</LINK>).</P>
<P>Open angle glaucoma is the most common form of glaucoma in white and African populations, whereas closed angle glaucoma is more common in Asian populations (<LINK REF="REF-Bonomi-2002" TYPE="REFERENCE">Bonomi 2002</LINK>; <LINK REF="REF-Tielsch-1991" TYPE="REFERENCE">Tielsch 1991</LINK>). In the USA, rates of POAG are reported to be four to five times greater in African-American populations compared to European-derived populations, with the rates for Mexican-Americans in between (<LINK REF="REF-Quigley-2001" TYPE="REFERENCE">Quigley 2001</LINK>; <LINK REF="REF-Tielsch-1991" TYPE="REFERENCE">Tielsch 1991</LINK>). The prevalence of POAG in Chinese populations is reported to be similar to European-derived populations, but is greater in populations from southern India compared to European-derived populations (<LINK REF="REF-Foster-2000" TYPE="REFERENCE">Foster 2000</LINK>; <LINK REF="REF-Ramakrishnan-2003" TYPE="REFERENCE">Ramakrishnan 2003</LINK>). According to a 2004 meta-analysis of population-based studies, OAG affects more than 2 million individuals in the USA, and due to the rapid aging of the US population, this number is estimated to increase to more than 3 million by 2020 (<LINK REF="REF-Friedman-2004" TYPE="REFERENCE">Friedman 2004</LINK>).</P>
<P>Primary open angle glaucoma is inherited as a complex trait, although environmental factors may also contribute to the disease (<LINK REF="REF-Hunter-2005" TYPE="REFERENCE">Hunter 2005</LINK>). Ocular hypertension, or high IOP, is one of the main risk factors for glaucoma, but is neither necessary nor sufficient to induce the neuropathy. Other risk factors for glaucoma include aging, positive family history of glaucoma in a first-degree relative, central corneal thickness less than 555 microns, high myopia (nearsightedness), and migraine headaches (<LINK REF="STD-Anderson-2003" TYPE="STUDY">Anderson 2003</LINK>; <LINK REF="REF-Armaly-1980" TYPE="REFERENCE">Armaly 1980</LINK>; <LINK REF="REF-Heijl-2002" TYPE="REFERENCE">Heijl 2002</LINK>), none of which is modifiable in an effort to reduce risk.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Presentation and diagnosis</HEADING>
<P>Open angle glaucoma is usually asymptomatic in the early stages. In some cases the disease may go unnoticed until unrecoverable damage to the optic nerve causes peripheral visual field defects. Without treatment there is a gradual loss of vision over time, ultimately leading to irreversible blindness.</P>
<P>In some patients the degeneration of the optic nerve occurs even while the IOP remains within the normal range. Glaucoma of this type is known as normal- or low-tension glaucoma, and is thought to represent a subtype of adult-onset OAG. The clinical appearance of the optic nerve in normal-tension glaucoma and in primary optic neuropathies is very similar. The distinction between high- and low-tension glaucoma is that people with high-tension glaucoma present with an IOP of 21 mmHg or more (<LINK REF="REF-Kamal-1998" TYPE="REFERENCE">Kamal 1998</LINK>).</P>
<P>In addition to measuring IOP when testing for glaucoma, it is equally important to perform a visual field test and to examine the optic nerve to establish the diagnosis of glaucoma. Measurements of the vertical cup-disc ratio, especially in relation to the optic disc size, may be useful in identifying potential cases of glaucoma (<LINK REF="REF-Garway_x002d_Heath-1998" TYPE="REFERENCE">Garway-Heath 1998</LINK>). In some patients, RGC death can be detected clinically by specific visual field loss (<LINK REF="REF-Schwartz-2000" TYPE="REFERENCE">Schwartz 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Treatment options</HEADING>
<P>Early detection and treatment of glaucoma is critical as progression of the disease will result in permanent blindness (<LINK REF="REF-Shields-1996" TYPE="REFERENCE">Shields 1996</LINK>). Once peripheral or central vision is lost due to glaucoma, no form of treatment can restore it. Most treatments for glaucoma continue to be directed at reducing IOP and slowing the disease progression, although for many patients the reduction of IOP by itself does not prevent optic nerve damage or visual field loss. Furthermore, studies have shown that the loss of RGCs continues despite lowering IOP (<LINK REF="REF-Brubaker-1996" TYPE="REFERENCE">Brubaker 1996</LINK>; <LINK REF="REF-Cockburn-1983" TYPE="REFERENCE">Cockburn 1983</LINK>). Interventions that only focus on reducing IOP thus may not be beneficial for some glaucoma patients.</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2017-01-12 04:59:34 +0000" MODIFIED_BY="[Empty name]">
<P>Treating disease by preventing neuronal death or deterioration is known as neuroprotection (<LINK REF="REF-Levin-1999" TYPE="REFERENCE">Levin 1999</LINK>). Different compounds, both natural and synthetic, have been reported to have neuroprotective activity. These include antioxidants, N-methyl-D-aspartate (NMDA) receptor antagonists, inhibitors of glutamate release, calcium channel blockers, polyamine antagonists and nitric synthase inhibitors, as well as cannabinoids, aspirin, melatonin, and vitamin B<SUB>12</SUB> (<LINK REF="REF-Neacsu-2003" TYPE="REFERENCE">Neacsu 2003</LINK>; <LINK REF="REF-Neufeld-1998" TYPE="REFERENCE">Neufeld 1998</LINK>; <LINK REF="REF-Weinreb-1999" TYPE="REFERENCE">Weinreb 1999</LINK>).</P>
<P>Neuroprotection for glaucoma refers to any intervention intended to protect the optic nerve or prevent the death of RGCs. The intervention can operate by affecting cellular factors derived from the optic nerve itself, or by eliminating risk factors external to the nerve (e.g. reducing IOP). In this review we considered oral and topical neuroprotective agents for all people with OAG regardless of IOP.</P>
<P>Neuroprotection occurs in addition to, and as a separate effect from, lowering IOP. If we consider lowering of IOP as an indirect approach for neuroprotection, and therefore a treatment for glaucoma, it may be necessary to supplement additional neuroprotective agents (<LINK REF="REF-Schwartz-2000" TYPE="REFERENCE">Schwartz 2000</LINK>; <LINK REF="REF-Weinreb-1999" TYPE="REFERENCE">Weinreb 1999</LINK>). Other neuroprotective interventions include neutralization of the toxicity of risk factors, for example the use of glutamate receptor antagonists or inhibitors of nitric oxide synthase can be considered as different approaches to neuroprotection (<LINK REF="REF-Neufeld-1997" TYPE="REFERENCE">Neufeld 1997</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2017-01-13 09:03:41 +0000" MODIFIED_BY="[Empty name]">
<P>Glaucoma is now recognized as a neurodegenerative disease associated with long-term progressive RGC death (<LINK REF="REF-Bathija-1998" TYPE="REFERENCE">Bathija 1998</LINK>; <LINK REF="REF-Quigley-1999" TYPE="REFERENCE">Quigley 1999</LINK>; <LINK REF="REF-Schwartz-1996" TYPE="REFERENCE">Schwartz 1996</LINK>). Some of the cellular processes that result in the death of RGCs and that are consequently targeted by neuroprotective agents, include the:</P>
<OL>
<LI>production of external nerve-derived risk factors such as glutamate and nitric oxide;</LI>
<LI>deprivation of internal trophic (nutritional) factors in the nerve cells;</LI>
<LI>loss of intracellular self repair processes; and</LI>
<LI>generation of intracellular destructive processes (<LINK REF="REF-Schwartz-2000" TYPE="REFERENCE">Schwartz 2000</LINK>).</LI>
</OL>
<P>The rationale for treatment is that by acting as pharmacological antagonists, neuroprotective agents can correct the imbalance between cellular death and survival signals, thus preventing RGC death and optic nerve damage. Also, self repair via neuroprotection may prevent the loss of RGC function by targeting the various processes involved in causing the death of RGCs. Since the loss of RGCs is the terminal process in the pathophysiology of glaucoma, neuroprotection may be helpful in preserving visual function (<LINK REF="STD-Chader-2012" TYPE="STUDY">Chader 2012</LINK>). However, there is still no consensus on the precise cause of glaucomatous optic neuropathy.</P>
</THEORY>
<IMPORTANCE MODIFIED="2017-01-12 05:10:15 +0000" MODIFIED_BY="[Empty name]">
<P>Glaucoma is a leading cause of permanent blindness worldwide. As a chronic and progressive condition, glaucoma is amenable to treatment in the early stages of disease. As such, many types of interventions have been proposed for the treatment of glaucoma. There is a published Cochrane review of topical treatments for the prevention of progression or onset of glaucomatous optic neuropathy (<LINK REF="REF-Vass-2007" TYPE="REFERENCE">Vass 2007</LINK>). In this review, we updated our evaluation of the evidence regarding the effects of neuroprotective agents when used to treat glaucoma. Consideration of the results of this review may lead health policy planners to improve access to prevention programs for glaucoma, encourage early detection and treatment of glaucoma, and stimulate development of new neuroprotective agents.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-01-12 05:11:51 +0000" MODIFIED_BY="[Empty name]">
<P>The objective of this review was to systematically examine the evidence regarding the effectiveness of neuroprotective agents for slowing the progression of OAG in adults compared with no neuroprotective agent, placebo, or other glaucoma treatment.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-01-17 17:05:47 +0000" MODIFIED_BY="Anupa Shah">
<SELECTION_CRITERIA MODIFIED="2017-01-17 17:05:47 +0000" MODIFIED_BY="Anupa Shah">
<CRIT_STUDIES MODIFIED="2017-01-17 17:05:47 +0000" MODIFIED_BY="Anupa Shah">
<P>We included only randomised controlled trials in the review.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-01-12 05:13:32 +0000" MODIFIED_BY="[Empty name]">
<P>We included trials of adults (age 30 years and older) who had OAG documented by: </P>
<OL>
<LI>at least two reliable visual fields demonstrating visual field loss compatible with glaucomatous damage (on the basis of mean deviation and corrected pattern standard deviation or corrected loss variance of Humphrey or Octopus perimetry); and</LI>
<LI>glaucomatous optic nerve changes.</LI>
</OL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-01-12 05:26:22 +0000" MODIFIED_BY="[Empty name]">
<P>We included trials that used topical and oral treatments to prevent RGC death. Such agents include:</P>
<UL>
<LI>pharmacological antagonists like memantine that inhibit excitotoxicity by binding to NMDA receptors and preventing excitatory activity;</LI>
<LI>alpha 2 adrenergic agonists like brimonidine;</LI>
<LI>calcium channel blocking agents;</LI>
<LI>delivery of brain-derived neurotrophic factor (BDNF) to RGC;</LI>
<LI>antioxidant and free radical scavengers;</LI>
<LI>
<I>Ginkgo biloba</I> extract;</LI>
<LI>nitric oxide synthase inhibitor.</LI>
</UL>
<P>We included trials that compared any of the above interventions with placebo or no intervention. We also included trials in which any of the above interventions had been compared to another or in which different regimens of the same intervention had been compared.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-01-13 14:50:22 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2017-01-12 05:33:03 +0000" MODIFIED_BY="[Empty name]">
<P>The primary outcome for this review was the proportion of participants who developed any progression of visual field loss at a follow-up of five years' postintervention. The effect of lowering IOP is better measured during longer follow-up (<LINK REF="REF-AGIS-1994" TYPE="REFERENCE">AGIS 1994</LINK>; <LINK REF="REF-Nouri_x002d_Mahdavi-2004" TYPE="REFERENCE">Nouri-Mahdavi 2004</LINK>). As of the 2013 update of the review (<LINK REF="REF-Sena-2013" TYPE="REFERENCE">Sena 2013</LINK>), we have included visual field loss after four years.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2017-01-13 14:50:22 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Visual acuity: the proportion of participants with loss of two or more lines of visual acuity measured by LogMAR chart. As a subgroup, we also compared differences between the treated group of participants who experienced progressive visual field loss and the untreated group of participants who experienced progressive visual field loss.</LI>
<LI>Intraocular pressure: differences in mean change in IOP in the treated group compared with the untreated group. As a subgroup, we also compared differences in mean IOP in the treated group of participants who experienced progressive visual field loss and the untreated group of participants who experienced progressive visual field loss.</LI>
<LI>Vertical cup-disc ratio: the proportion of participants with asymmetrical vertical cup-disc ratio greater than 0.3.</LI>
</OL>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<P>We reported adverse effects related to the particular treatment reported in the included studies. These included any ocular and systemic side effects that occurred during the treatment period, tolerability, any abnormal ocular finding, or any adverse event. We defined an adverse event as any undesirable event occurring in a participant, whether or not considered to be related to the study treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life measures</HEADING>
<P>We planned to summarize any quality of life data reported in the included studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Economic data</HEADING>
<P>We planned to summarize any economic data including, but not limited to, cost-effectiveness and cost-benefit analyses reported in the included studies. Economic data included direct costs associated with the treatment follow-up, estimated and calculated per participant, and indirect costs such as transportation and expenses necessary to the medical follow-up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Follow-up</HEADING>
<P>We aimed to include trials with at least five years of follow-up to allow for adequate assessment of the effect of neuroprotection on prevention of visual field loss. For the 2013 update of the review, we revised the minimum follow-up time to include studies with at least four years of follow-up because the editorial reviewers indicated that four years may be a sufficient amount of time to detect differences between treatment groups (<LINK REF="REF-Sena-2013" TYPE="REFERENCE">Sena 2013</LINK>).</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-01-13 09:08:53 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2017-01-13 09:08:53 +0000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 7), Ovid MEDLINE, Epub Ahead of Print, In-Process &amp; Other Non-Indexed Citations, Ovid MEDLINE Daily (January 1946 to August 2016), Embase (January 1980 to August 2016), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to August 2016), the ISRCTN registry (<A HREF="http://www.isrctn.com/editAdvancedSearch">www.isrctn.com/editAdvancedSearch</A>), ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://www.who.int/ictrp/search/en">www.who.int/ictrp/search/en</A>). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 16 August 2016.</P>
<P>See: Appendices for details of search strategies for CENTRAL (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), MEDLINE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), Embase (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), LILACS (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), the ISRCTN (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>), ClinicalTrials.gov (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>), and the ICTRP (<LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2017-01-12 05:59:27 +0000" MODIFIED_BY="[Empty name]">
<P>We manually searched the reference lists of publications from the included study to identify additional trials. We also used the Science Citation Index to screen studies that cited any included study to identify additional trials (last searched 30 November 2016).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-01-13 14:51:45 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2017-01-12 06:07:39 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors (DS and KL) independently reviewed titles and abstracts resulting from the literature searches according to the inclusion criteria described above. We classified the abstracts as 'relevant,' 'potentially relevant,' or 'definitely not relevant.' We obtained the full-text report of those in the 'relevant' or 'potentially relevant' categories and assessed the studies they reported for inclusion. We resolved any disagreements through discussion. When necessary, we contacted the authors of studies for clarification of eligibility. For all studies excluded after review of the full text, we documented the reasons for exclusion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-01-13 14:51:18 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors (DS and KL) independently extracted data from the reports of the one included study using data extraction forms developed by Cochrane Eyes and Vision and adapted for this review. We extracted the following data: country of clinical trial; age and gender of participants; trial design; details of the interventions including doses, route of administration, and duration of treatment; follow-up schedule and timing of outcome measurements; participant flow charts and the associated numbers. We also recorded details of the methods used to ascertain outcomes. We anticipated that certain parameters, such as visual field, would be measured by differently in different trials; we thus extracted any reported outcome related to visual field from the included trial. Any discrepancies between the two review authors were resolved by discussion. One review author (KL) entered data into Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), and a second review author (DS) verified the data.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-01-12 06:29:14 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors (DS and KL) independently assessed the included studies for risk of bias according to guidelines set out in Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We considered methods employed to address the following systematic biases to determine the methodological quality of each study.</P>
<UL>
<LI>Selection bias (sequence generation and allocation concealment before randomization): We considered any method of allocation concealment such as centralized randomization or use of sequential, opaque envelopes, which provides reasonable confidence that the allocation sequence was concealed from physicians and participants, to confer 'low risk of bias.' When the allocation was based on unconcealed lists or envelopes, or there was no qualifying statement describing allocation method or timing, we assessed the study as having 'unclear risk of bias.'</LI>
<LI>Masking of participants and care providers with regard to treatment allocation to assess for performance bias.</LI>
<LI>Masking of outcome assessors to assess detection bias.</LI>
<LI>Rates of follow-up, reasons for loss to follow-up, and analysis by the intention-to-treat principle to assess for attrition bias. We considered a trial to have been analyzed by the intention-to-treat principle that analyzed participants as randomized, and included participants for whom no outcome measurements were made and those who received only part or none of the intended treatment.</LI>
<LI>Selective outcome reporting was examined to assess reporting bias.</LI>
</UL>
<P>Any disagreements between the review authors were resolved through discussion. We did not need to contact the authors of any included study for additional information related to risk of bias.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2017-01-12 06:33:24 +0000" MODIFIED_BY="[Empty name]">
<P>As this review included only one study, we performed no meta-analysis. If in the future additional studies are included and meta-analysis is deemed appropriate, we will perform data analysis according to the guidelines in Chapter 9 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). We reported dichotomous outcomes using risk ratios and continuous outcomes using mean differences. We planned to use the standardized mean difference to summarize outcomes measured on different scales.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-12-16 20:27:31 +0000" MODIFIED_BY="[Empty name]">
<P>The unit of analysis was the individual participant.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2017-01-12 06:36:05 +0000" MODIFIED_BY="[Empty name]">
<P>We did not contact primary investigators from the only included study, as the desired data were provided in the published reports. In the future when additional information is needed, we will contact primary investigators of trials for unreported outcome data. We did not impute outcome data for the purposes of this review.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2017-01-13 14:51:45 +0000" MODIFIED_BY="[Empty name]">
<P>As this review included only one study, we did not assess heterogeneity across studies. When additional studies are included in future updates, we will assess clinical heterogeneity qualitatively before performing statistical analysis. When the participants in the included trials differ in any substantial way, we will take note and decide whether to perform meta-analysis. We will examine study characteristics and symmetry of the forest plots. We will interpret a poor degree of overlap of the confidence intervals on the effect estimates from the studies included in a meta-analysis as indicative of statistical heterogeneity. The effect estimates across studies will be tested for inconsistency using the Chi<SUP>2</SUP> test and quantified using the I<SUP>2</SUP> statistic. An I<SUP>2</SUP> statistic greater than 50% will indicate the presence of substantial statistical heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2017-01-12 22:32:38 +0000" MODIFIED_BY="[Empty name]">
<P>We will use a funnel plot to identify publication bias whenever 10 or more studies are included in a meta-analysis. We also assessed selective outcome reporting as part of our 'Risk of bias' assessment.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2017-01-12 22:35:27 +0000" MODIFIED_BY="[Empty name]">
<P>We aimed to synthesize data both qualitatively and quantitatively. We planned to combine the effect estimates in a meta-analysis using a random-effects model whenever appropriate. We planned to use a fixed-effect model when the number of included trials was fewer than three. If there was significant clinical heterogeneity, or the I<SUP>2</SUP> statistic was greater than 50%, we planned not to present a meta-analysis in such cases; instead, we would present a tabulated summary, narrative summary, or both.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-12-10 18:06:56 +0000" MODIFIED_BY="[Empty name]">
<P>As a subgroup, we compared differences between the treated group of participants that developed progressive visual field loss and the untreated group of participants that developed progressive visual field loss for visual acuity and IOP outcomes.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2017-01-12 22:38:41 +0000" MODIFIED_BY="[Empty name]">
<P>When data were sufficient, we planned to examine the impact of excluding studies at high risk of bias, unpublished data, and industry-funded studies through sensitivity analyses.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings</HEADING>
<P>We have presented a 'Summary of findings' table with the estimated effects for the outcomes assessed in this review. We used the GRADE approach to assess the certainty of evidence for each outcome (<LINK REF="REF-GRADEpro-2014" TYPE="REFERENCE">GRADEpro 2014</LINK>). Two review authors (DS and KL) independently graded the certainty of each outcome estimate as very low, low, moderate, or high according to five criteria: risk of bias within individual studies, indirectness of comparisons, heterogeneity among studies, imprecision of estimate (wide confidence intervals), and publication bias. Any discrepancies were resolved by discussion.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-01-16 17:49:24 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2017-01-12 23:09:21 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2017-01-12 22:54:41 +0000" MODIFIED_BY="[Empty name]">
<P>The original electronic searches run in 2010 yielded 1500 records of articles, abstracts, and reviews. We obtained full-text copies of 24 potentially relevant records and evaluated the studies for inclusion. We also reviewed 11 additional articles identified by screening the reference lists of full-text articles. Of the 35 full-text reports we reviewed, which reported 29 studies, none met all the inclusion criteria for this review. Of the 29 studies excluded at this stage, six were not randomized trials; six did not involve people with OAG or did not limit the study to people with OAG; two did not compare the interventions of interest for this review; and 15 were short-term trials, between two hours and four years, and thus did not meet the five-year follow-up period specified for the review in 2010.</P>
<P>Through a search of the ClinicalTrials.gov database, we identified two phase III trials investigating the effects of memantine in people with chronic glaucoma (<LINK REF="STD-NCT00141882" TYPE="STUDY">NCT00141882</LINK>; <LINK REF="STD-NCT00168350" TYPE="STUDY">NCT00168350</LINK>). Both studies were conducted by Allergan Inc. and are described as randomized, double-masked, placebo-controlled, parallel-assignment studies. Data for the first trial were not published, but two review papers reported them to show potential beneficial effects (<LINK REF="REF-Cheung-2008" TYPE="REFERENCE">Cheung 2008</LINK>; <LINK REF="REF-McKinnon-2008" TYPE="REFERENCE">McKinnon 2008</LINK>). The results of the second trial failed to corroborate the results of the first trial. Reports of the second trial publicly released by Allergan Inc. indicated that progression of glaucoma was significantly lower in participants receiving high-dose memantine compared with participants receiving low-dose memantine, but that there was no significant effect compared with participants receiving placebo. These trials are awaiting classification for inclusion in this review because the follow-up times for outcome measurements are unclear.</P>
<P>We updated the electronic search on 16 October 2012 and identified 655 new records. At this time, we modified the eligibility criteria for this review to include studies with four or more years of follow-up based on feedback from external content experts. One of the studies identified by the original electronic searches in 2010 became eligible based on this change (<LINK REF="STD-LoGTS-2011" TYPE="STUDY">LoGTS 2011</LINK>). Of the 655 new records identified, we excluded 638 by screening titles and abstracts, and reviewed full-text documents for 17 records. Of the 17 full-text reports reviewed, we excluded 14 and included three in the review. These three records were reports from one study, <LINK REF="STD-LoGTS-2011" TYPE="STUDY">LoGTS 2011</LINK>.</P>
<P>We updated the electronic searches on 16 August 2016 (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Of 1294 new records identified, we excluded 1283 by screening titles and abstracts and 11 after reviewing the full-text reports. The 11 excluded full-text reports were from eight studies. We identified no other potentially relevant records from searching other sources.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2017-01-12 23:05:29 +0000" MODIFIED_BY="[Empty name]">
<P>We included one study in this review (<LINK REF="STD-LoGTS-2011" TYPE="STUDY">LoGTS 2011</LINK>). <LINK REF="STD-LoGTS-2011" TYPE="STUDY">LoGTS 2011</LINK> was a multicenter randomized controlled trial of people with low-pressure glaucoma conducted in the USA. Brimonidine, an alpha 2 adrenergic agonist and neuroprotective agent, was compared with timolol, a beta-adrenergic receptor blocker and IOP-lowering agent, over a four-year treatment period. Participants and study investigators were masked to treatment groups. All study participants discontinued topical ocular hypotensive medications, and there was a washout period prior to beginning study interventions.</P>
<P>The 190 study participants included men and women 30 years of age or older with untreated glaucoma and IOP of 21 mmHg or less. After randomization, 12/190 (6%) of the study participants were excluded due to the exclusion of a study site (10 participants), withdrawal of consent (one participant), or because the participant did not meet study eligibility criteria (one participant). Of the 178 participants who remained in the study, 99 had been randomized to receive brimonidine tartrate 0.2% monotherapy (Alphagan; Allergan Inc., Irvine, California, USA) and 79 had been randomized to receive timolol maleate 0.5% monotherapy (Timoptic; Merck &amp; Co., West Point, Pennsylvania, USA). Both treatment solutions contained benzalkonium chloride (0.005% (50 ppm) in brimonidine, and 0.01% (100 ppm) in timolol) and were instilled in both eyes twice a day. The primary outcome of the study was progression of visual field loss. After one year of follow-up, 36/99 (36%) participants in the brimonidine group and 8/79 (10%) participants in the timolol group had missing outcome data, and after four years of follow-up, 54/99 (55%) participants in the brimonidine group and 23/79 (29%) participants in the timolol group had missing outcome data.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-01-12 23:09:21 +0000" MODIFIED_BY="[Empty name]">
<P>We excluded 49 studies from the review following the full-text assessment of reports. Thirteen were not randomized trials; six did not enroll participants with OAG, or did not limit the study to participants with OAG; four did not compare the interventions of interest for this review; and 26, with between two hours' and three years' follow-up, did not meet the fours years' follow-up requirement for inclusion in this review.</P>
<P>See: <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> for further details.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-01-13 09:14:19 +0000" MODIFIED_BY="[Empty name]">
<ALLOCATION MODIFIED="2017-01-12 23:12:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-LoGTS-2011" TYPE="STUDY">LoGTS 2011</LINK> was a randomized controlled trial. The randomization list was computer generated and maintained during the study by supplying coded study medications to the clinical centers. For these reasons, we assessed the risk of selection bias related to sequence generation and allocation concealment to be low.</P>
<SUBSECTION>
<HEADING LEVEL="3">Masking (performance bias and detection bias)  </HEADING>
<P>"Full masking of patients, physicians, technicians, and the reading center for visual fields and optic disc photographs" was reported in <LINK REF="STD-LoGTS-2011" TYPE="STUDY">LoGTS 2011</LINK>. Furthermore, analysis of visual fields, the primary outcome of the trial, was masked. For these reasons, we judged the study to be at low risk of performance and detection bias.</P>
</SUBSECTION>
</ALLOCATION>
<EXCLUSIONS MODIFIED="2017-01-12 23:22:45 +0000" MODIFIED_BY="[Empty name]">
<P>To assess risk of attrition bias, we considered:</P>
<OL>
<LI>exclusion of participants after randomization;</LI>
<LI>rates of loss to follow-up;</LI>
<LI>handling of missing data.</LI>
</OL>
<P>The total number of participants stated as enrolled in the study differed between trial reports (<LINK REF="STD-LoGTS-2011" TYPE="STUDY">LoGTS 2011</LINK>). The authors of the design and baseline paper, published in 2005, reported that 190 participants were randomized (number assigned to each treatment group was not specified). In the results paper, published in 2011, the study investigators reported that 178 participants were randomized. We considered 12/190 (6%) participants to have been excluded from the study based on the difference between the 2005 and 2011 study reports.</P>
<P>There were differential losses to follow-up between the brimonidine and timolol groups at one and four years of follow-up. At one year, 36/99 (36%) participants in the brimonidine group were lost to follow-up, compared with 8/79 (10%) participants in timolol group (P &lt; 0.001). Allergy to the study medication was the most common reason for participants dropping out of the study and was greater in the brimonidine group (20/99 participants in brimonidine group compared with 3/79 participants in timolol group). At four years' follow-up, 54/99 (55%) participants in brimonidine group and 23/79 (29%) participants in timolol group were lost to follow-up (P &lt; 0.001).</P>
<P>With reference to the study design of <LINK REF="STD-LoGTS-2011" TYPE="STUDY">LoGTS 2011</LINK>, a participant was withdrawn from the study whenever: the IOP increased to more than 21 mmHg; visual field loss progressed; allergy or intolerance to a study medication developed; or the treating ophthalmologist decided that the participant should be discontinued from the study. The proportions of participants analyzed at the four-year follow-up time for the primary visual field outcome were 45/99 (45%) in the brimonidine group and 56/79 (71%) in the timolol group. Data were thus missing for 89/190 (47%) participants at the four-year follow-up time, so that no conclusions can be drawn from this study with regard to neuroprotective effects for the participants with missing data or overall.</P>
<P>Due to the exclusion of participants after randomization, the differential rates of loss to follow-up between the study groups, and inadequate handling of missing data, we assessed the study to have a high risk of attrition bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2017-01-12 23:27:34 +0000" MODIFIED_BY="[Empty name]">
<P>The authors of <LINK REF="STD-LoGTS-2011" TYPE="STUDY">LoGTS 2011</LINK> specified primary and secondary outcomes related to progression of visual field loss, but the ranking of the outcomes differed between the design and baseline paper published in 2005 and the results paper published in 2011. In the 2005 design report, the primary outcome was defined as "significant progression of the same two or more points, on the Humphrey glaucoma change probability maps or by Progressor linear regression analysis, in 3 consecutive (over an 8-month period) Humphrey 24-2 full threshold fields." In the 2011 results paper, the outcome for visual field was separated into a primary outcome ("the primary outcome measure was visual field progression in either eye as determined by pointwise linear regression analysis of all study visual fields with Progressor software (Medisoft Inc., Leeds, UK)" and a secondary outcome ("a secondary outcome was visual field progression in either eye evaluated by Humphrey glaucoma change probability maps (GCPM)").</P>
<P>Although not specified as outcomes for the study, other measures relevant to glaucoma and targeted for this review were recorded at follow-up visits: IOP, visual acuity, changes to optic nerve structure, and cup-disc ratio. Due to the variation in outcome definitions between the published reports, and failure to report other outcomes that were measured and that are commonly reported in glaucoma trials, we judged the study to have a high risk of reporting bias.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2017-01-13 09:14:19 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria for this study allowed for the inclusion of one or both eyes of participants, and non-independence of eyes was taken into account when both eyes were included. Although the study was "patient-based," progression of visual field loss was based on the first eye with progression when both eyes were included. The authors did not report progression findings in the second eye after one eye progressed.</P>
<P>The study was partially funded by Allergan Inc. through an unrestricted grant and the provision of study medications. Additional funding support included an unrestricted grant from Research to Prevent Blindness Inc. (New York, New York, USA).</P>
<P>Due to issues related to the unit of analysis and industry source of funding, we assessed the study as having other potential sources of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-01-16 17:49:24 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Brimonidine 0.2% versus timolol 0.5%</HEADING>
<P>A summary of the effects of interventions is provided in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Progression of visual field loss</HEADING>
<P>Progression of visual field loss was the primary outcome of <LINK REF="STD-LoGTS-2011" TYPE="STUDY">LoGTS 2011</LINK>. Three methods were used to measure visual fields:</P>
<OL>
<LI>Progressor pointwise linear regression analysis;</LI>
<LI>Humphrey glaucoma change probability maps using pattern deviation; and</LI>
<LI>the 3-omitting method for pointwise linear regression analysis.</LI>
</OL>
<P>Agreement among the three methods for detecting progression of visual field loss was good (overall kappa of 0.628, standard error (SE) = 0.051), with the highest agreement between the Progressor pointwise linear regression and 3-omitting method (kappa of 0.719, SE = 0.068) and the lowest agreement between glaucoma change probability maps and 3-omitting method (kappa of 0.554, SE = 0.079).</P>
<P>At the four-year follow-up examination, 5/45 participants in the brimonidine group and 18/56 participants in the timolol group had progression of visual field loss detected by all three methods (risk ratio (RR) 0.35, 95% confidence interval (CI) 0.14 to 0.86). However, these results do not take into account the higher rate of missing data in the brimonidine group compared with the timolol group (data missing for 55% of participants in brimonidine group versus 29% of participants in timolol group). Due to the amount of missing data and the imbalance between groups in participants followed up and selective reporting bias, we graded the certainty of evidence for this outcome as very low.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Visual acuity</HEADING>
<P>The study authors reported that linear regression slopes of the Snellen decimal visual acuity fraction was not statistically different between treatment groups among participants with progression of visual field loss, participants completing the four-year follow-up without progression of visual field loss, or participants who did not complete the one-year follow-up. However, no data were available to compare visual acuity outcomes between treatment groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intraocular pressure</HEADING>
<P>At the four-year follow-up examination, mean IOP was similar in the two treatment groups. Mean IOP was 14.2 mmHg (standard deviation (SD) = 1.9) among the 43 participants with data available in the brimonidine group and 14.0 mmHg (SD = 2.6) among the 48 participants with data available in the timolol group (mean difference 0.20 mmHg, 95% CI -0.73 to 1.13). Among the participants who experienced progressive visual field loss, IOP reduction of 20% or greater did not differ significantly between groups: 4/9 participants in the brimonidine group and 12/31 participants in the timolol group with visual field loss, as determined by Progressor pointwise linear regression analysis, had IOP reduction of 20% or greater at time of further visual field loss (RR 1.15, 95% CI 0.49 to 2.70). Due to the amount of missing data and the imbalance between treatment groups in the number of participants followed up and selective reporting bias, we graded the certainty of evidence for IOP outcomes as very low.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Vertical cup-disc ratio</HEADING>
<P>Vertical cup-disc ratio outcomes were not reported in <LINK REF="STD-LoGTS-2011" TYPE="STUDY">LoGTS 2011</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>The most common adverse effect was ocular allergy to the study medication that required discontinuation. Allergic reactions occurred among more brimonidine participants (20/99 discontinued the study for this reason) compared with timolol participants (3/79 discontinued the study for this reason) (RR 5.32, 95% CI 1.64 to 17.26). Six participants, five in the brimonidine group and one in the timolol group, died during the study due to causes unrelated to the study treatments (trauma, myocardial infarction, pulmonary embolism, or complications from bowel surgery).</P>
<P>We graded the certainty of evidence for adverse effects as very low due to the amount of missing data and the imbalance between groups in numbers of participants followed up and selective reporting bias.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-01-13 14:54:22 +0000" MODIFIED_BY="[Empty name]">
<P>Glaucoma is understood to be a progressive neurodegenerative disease, therefore medical therapies that focus directly on protecting the optic nerve and preventing the death of RGCs should play a role in the future of glaucoma treatment. Furthermore, studies have shown that interventions intended to only lower IOP, the most common risk factor for glaucoma progression, are not always effective in preventing visual field loss (<LINK REF="REF-Brubaker-1996" TYPE="REFERENCE">Brubaker 1996</LINK>; <LINK REF="REF-Cockburn-1983" TYPE="REFERENCE">Cockburn 1983</LINK>). Considered by some to be a complementary or alternative therapy (<LINK REF="REF-NICE-Guidelines" TYPE="REFERENCE">NICE Guidelines</LINK>), neuroprotective treatment for glaucoma endeavors to preserve vision by preventing, slowing, or reversing the death of RGCs. For the purpose of examining the evidence according to this definition of neuroprotection, the scope of this review was limited by the inclusion criteria to identify studies with long-term outcomes directly related to visual field defects or to the optic nerve itself.</P>
<SUMMARY_OF_RESULTS MODIFIED="2017-01-13 00:08:25 +0000" MODIFIED_BY="[Empty name]">
<P>After failure to identify any eligible study with five or more years of follow-up, we examined findings from one randomized controlled trial that had compared brimonidine 0.2% with timolol 0.5% and aimed to follow participants for four years (<LINK REF="STD-LoGTS-2011" TYPE="STUDY">LoGTS 2011</LINK>). Outcome data were derived from 99 participants randomized to the brimonidine monotherapy group and 79 participants randomized to the timolol monotherapy group. Although results from the four-year follow-up examination suggested that brimonidine may slow or prevent visual field loss compared with timolol, these estimates ignore the higher number of participants with missing data in the brimonidine group compared with the timolol group (55% versus 29%, respectively). Subgroup analyses of participants who experienced progression of visual field loss, participants who completed the study without progression, and participants who did not complete the study did not show any statistical differences between treatment groups in terms of the rate of change of Snellen decimal visual acuity fraction during follow-up. At the four-year follow-up, mean IOP was similar in the two treatment groups. The study investigators did not report vertical cup-disc ratios during follow-up or changes over time. More participants in the brimonidine group experienced adverse events compared with the timolol group, with ocular allergy to the study medication that required discontinuation being the most common adverse event (5.32 times more participants affected in the brimonidine group compared with the timolol group, 95% CI 1.64 to 17.26).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2017-01-13 00:18:31 +0000" MODIFIED_BY="[Empty name]">
<P>The outcomes targeted in this review were specific to OAG. The population of interest was restricted to people with OAG and did not include people with ocular hypertension, thus prevention of glaucoma by neuroprotection was not addressed in this review. Furthermore, although the treatment of ocular hypertension is a method commonly used to prevent glaucoma and delay vision loss, it should be considered as a separate or adjunct focus for prevention since glaucoma can occur in the absence of increased IOP (<LINK REF="REF-AAO-Preferred-Practice-Pattern" TYPE="REFERENCE">AAO Preferred Practice Pattern</LINK>). Although the study authors of <LINK REF="STD-LoGTS-2011" TYPE="STUDY">LoGTS 2011</LINK> reported visual field outcomes and noted that annual optic nerve photographs were taken, they have not reported the correlation between visual field function and optic nerve structure changes in their results paper. Comparisons of optic nerve or retinal nerve fiber layer changes, or both, with the visual field changes would be of interest.</P>
<P>We defined the primary outcome for this review as the proportion of participants who had experienced any progression of visual field loss at four years' postintervention. This outcome is consistent with current recommendations for visual function endpoints for ophthalmic studies (<LINK REF="REF-Csaky-2008" TYPE="REFERENCE">Csaky 2008</LINK>). Although the reduction of IOP has been the outcome of interest in previous research (<LINK REF="REF-Danesh_x002d_Meyer-2009" TYPE="REFERENCE">Danesh-Meyer 2009</LINK>), it was not the primary focus of this review since lowering IOP alone is not always effective in preventing visual field loss from glaucoma. We included mean change in IOP as a secondary outcome, as it is currently the most common risk factor for glaucoma disease progression, and reduction may be beneficial for some patients (<LINK REF="REF-Seong-2009" TYPE="REFERENCE">Seong 2009</LINK>). Furthermore, the Collaborative Normal Tension Glaucoma Study showed that a 30% reduction in IOP yielded significant benefit; since that report was published, a 30% reduction in IOP has become the standard of glaucoma care because it is a strong predictor of glaucomatous damage (<LINK REF="STD-CNTGS-1998" TYPE="STUDY">CNTGS 1998</LINK>). The study design of <LINK REF="STD-LoGTS-2011" TYPE="STUDY">LoGTS 2011</LINK> allowed participants with any pressure below 21 mmHg to enroll; IOP data were reported only for those participants with 20% reduction in IOP and progressive visual field loss.</P>
<P>After one year, 36/99 (36%) participants in the brimonidine group and 8/79 (10%) participants in the timolol group had been lost to follow-up; by four years, 54/99 (55%) participants in the brimonidine group and 23/79 (29%) participants in the timolol group had been lost to follow-up. Due to excessive attrition, we cannot conclude that brimonidine is more effective than timolol, as those participants not followed up may have had better or worse outcomes; the outcome estimates may therefore not be generalizable to the clinical setting.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2017-01-13 00:25:45 +0000" MODIFIED_BY="[Empty name]">
<P>As noted above, there was a differential amount of missing data between treatment groups in <LINK REF="STD-LoGTS-2011" TYPE="STUDY">LoGTS 2011</LINK>. The high attrition rate and the difference in attrition between groups suggest a high risk of attrition bias in estimates of outcomes. Four-year outcome data were missing for the majority of participants in the brimonidine group, thus results from this study are inconclusive. We therefore judged the certainty of evidence for the outcomes in this review to be very low.</P>
<P>The study criteria allowed for the inclusion of one or both eyes of participants. Although outcomes in the two eyes could be correlated, the study investigators did not account for non-independence of the two eyes. Participants were withdrawn from the study once further visual field loss was detected in the first eye.</P>
<P>With regard to reporting bias, the definition of primary and secondary outcomes differed between the published baseline paper and the results paper. The study investigators did not explain the change when they reported four-year outcomes. Also, some outcomes that were measured were not reported (i.e. cup-disc ratio, visual acuity for all participants, changes to optic nerve structure).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2017-01-13 00:27:29 +0000" MODIFIED_BY="[Empty name]">
<P>We attempted to minimize bias in the review process by conducting an extensive, highly sensitive search of the literature. Two review authors independently executed all steps in screening references, extracting data, and assessing studies. We consulted with glaucoma specialists and methodologists during the review process.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2017-01-13 14:54:22 +0000" MODIFIED_BY="[Empty name]">
<P>The endpoint for the primary outcome of this review was set at four years' postintervention to assess the long-term effects of neuroprotection. As such, we excluded 21 potentially relevant trials with a follow-up ranging from two hours to three years. Five of these studies reported results for visual outcomes at follow-up times of two years or greater (<LINK REF="STD-Araie-2010" TYPE="STUDY">Araie 2010</LINK>; <LINK REF="STD-Drance-1998" TYPE="STUDY">Drance 1998</LINK>; <LINK REF="STD-Garcia_x002d_Medina-2015" TYPE="STUDY">Garcia-Medina 2015</LINK>; <LINK REF="STD-Koseki-1999" TYPE="STUDY">Koseki 1999</LINK>; <LINK REF="STD-Sawada-1996" TYPE="STUDY">Sawada 1996</LINK>).</P>
<P>The excluded study with the longest follow-up time, three years, was conducted in Japan and included participants with normal-tension glaucoma (NTG) and mild to moderate damage (<LINK REF="STD-Araie-2010" TYPE="STUDY">Araie 2010</LINK>). The aim of the study was to determine the rates of visual field loss among participants given nipradilol 0.25% versus timolol 0.5%. Of the 158 randomized participants, 146 met the study eligibility criteria and were included in the analyses (72 participants received nipradilol and 74 received timolol). During the study, 13/72 (18%) participants in the nipradilol group and 11/74 (15%) participants in the timolol group were withdrawn due to adverse events; loss to follow-up; use of restricted drugs; complications not related to study treatment; and change of address. At three years, the study authors concluded that there was no significant difference between treatments in terms of overall visual field loss (mean deviation ± SE: &#8722;0.03 ± 0.06 decibels/year in nipradilol group and &#8722;0.05 ± 0.06 decibels/year in timolol group), but the superior-central subfield and the corrected pattern standard deviation measures were significantly changed within treatment groups compared with baseline (P &#8804; 0.001). Among subgroups of participants with early visual field loss or younger participants, nipradilol showed some benefit in slowing visual field deterioration compared with timolol (mean deviation 0.29 in nipradilol group versus -0.20 in timolol group, P = 0.005 for participants with stage 1 classification; mean deviation 0.15 in nipradilol group versus -0.23 in timolol group, P = 0.039 for participants 40 years of age or younger).</P>
<P>The study with the second-longest follow-up time, of two and a half years, was also conducted in Japan, by Sawada and colleagues (<LINK REF="STD-Sawada-1996" TYPE="STUDY">Sawada 1996</LINK>). The study was a randomized, prospective investigation of the effect of oral brovincamine fumarate (Sabromin; 20 mg three times daily) compared to placebo (three times daily) in participants with NTG. Brovincamine fumarate is a calcium channel blocker. In Sawada's study, 28 participants were allocated to receive either brovincamine or placebo. Visual fields were tested every four months using a Humphrey Field Analyzer, with mean follow-ups of 39.1 ± 8.7 months for the treatment group and 37.9 ± 10.1 months for the placebo group. With reference to visual fields analysis, 6/14 eyes in the treatment group had visual field improvement and 8/14 had no visual field improvement. In the control group, 12/14 had no visual field changes and 2/14 had an increased visual field loss. This study reported a beneficial effect of brovincamine on visual field in some participants with NTG, however the study was unable to provide a definitive conclusion due to the small number of participants included in the trial (14 in the brovincamine-treated group and 14 in the placebo-treated group). We contacted the lead author of this study and he informed us that data for longer follow-up times were not collected as brovincamine had become unavailable in Japan. </P>
<P>
<LINK REF="STD-Koseki-1999" TYPE="STUDY">Koseki 1999</LINK> investigated the effect of oral brovincamine on further deterioration of the visual field in participants with NTG. Participants with IOP less than 15 mmHg were randomly assigned to a group receiving oral brovincamine (20 mg three times daily) or an untreated control group for two years. This study reported that oral brovincamine may retard further visual field deterioration in participants with NTG who have low to normal IOP, however the study enrolled only a small group of participants (22 in the brovincamine group and 26 in the control group). The authors commented that the slightly better visual field performance during the study period in the brovincamine group may have been attributed to an improvement in cerebral function caused by cerebral vasodilatation rather than a reflection of protection from further glaucomatous damage.</P>
<P>
<LINK REF="STD-Drance-1998" TYPE="STUDY">Drance 1998</LINK> investigated the effects of betaxolol, timolol, and pilocarpine on visual functions in people with OAG. A total of 68 participants were randomized to receive one of the three treatments, and visual outcomes were measured after two years. No significant difference was reported for visual field effects between the treatment groups. The author did note that although all three treatments were effective in reducing IOP, there was dissociation between reduction of IOP and protection of visual function.</P>
<P>The fifth excluded study with visual outcomes at follow-up times of two years or greater was <LINK REF="STD-Garcia_x002d_Medina-2015" TYPE="STUDY">Garcia-Medina 2015</LINK>. Participants with primary open angle glaucoma were randomly assigned to one of three groups: oral antioxidant supplementation with omega-3 fatty acids; oral antioxidant supplementation without omega-3 fatty acids; and control. The authors reported no difference in visual field global indices between the treatment groups after two years. This study was presented as a conference abstract; the full report has yet to be published.</P>
<P>We identified two potentially relevant phase III trials assessing the effects of memantine in people with chronic glaucoma (<LINK REF="STD-NCT00141882" TYPE="STUDY">NCT00141882</LINK>; <LINK REF="STD-NCT00168350" TYPE="STUDY">NCT00168350</LINK>). Memantine has been theorized as a promising neuroprotective agent for the treatment of glaucoma that may work by blocking N-methyl-D-aspartate glutamate receptors, which may play a role in RGC death (<LINK REF="REF-Levin-2008" TYPE="REFERENCE">Levin 2008</LINK>; <LINK REF="REF-Lipton-2003" TYPE="REFERENCE">Lipton 2003</LINK>). Positive results from preclinical data suggesting a possible clinical benefit of memantine led to clinical trials being done in humans (<LINK REF="REF-Hare-2009" TYPE="REFERENCE">Hare 2009</LINK>; <LINK REF="REF-Ju-2009" TYPE="REFERENCE">Ju 2009</LINK>; <LINK REF="REF-Zhong-2007" TYPE="REFERENCE">Zhong 2007</LINK>). Both of the phase III memantine trials were randomized, placebo-controlled trials conducted by Allergan Inc. To date, Allergan has not published the results of either trial, but has reported via press releases that potential beneficial effects of memantine observed in the first trial were not supported by the second trial (<LINK REF="REF-Cheung-2008" TYPE="REFERENCE">Cheung 2008</LINK>; <LINK REF="REF-McKinnon-2008" TYPE="REFERENCE">McKinnon 2008</LINK>).</P>
<P>The aim of our systematic review was to summarize the evidence related to the effectiveness of different topical and oral neuroprotective agents for treating OAG in adults. Thus far, we have not identified any randomized trial providing convincing evidence for neuroprotective benefit regarding preventing or slowing visual field loss in OAG.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-01-13 05:08:26 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2017-01-13 05:00:21 +0000" MODIFIED_BY="[Empty name]">
<P>Recently there has been a growing interest in using neuroprotective drugs for the treatment of glaucoma. Neuroprotective agents such as pharmacological antagonists that inhibit excitotoxicity by activation, and N-methyl D-aspartate receptors like memantine; alpha 2 adrenergic agonists like brimonidine; calcium channel blocking agents; deliverers of brain-derived neurotrophic factor to retinal ganglion cells (RGCs); antioxidants and free radical scavengers; <I>Ginkgo biloba</I> extract; and nitric oxide synthase inhibitors have shown promise in preventing or slowing RGC death in preclinical studies. However, the current evidence has not shown topical or oral neuroprotective agents to be effective in preventing RGC death or in preserving the visual field in people with open angle glaucoma (OAG).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-01-13 05:08:26 +0000" MODIFIED_BY="[Empty name]">
<P>Although a fair amount of cellular and animal research has been completed, the effectiveness of neuroprotective oral and topical medical therapy for treating OAG in adults remains inconclusive. Further research is needed in this area, however there are certain research challenges (commitment of researchers and participants to long-term follow-up for study outcomes, even if treatment is modified or halted; selection of patient-important outcomes; accounting for variability of disease manifestations, etc.). Future studies should be designed to measure clinically meaningful outcomes, such as progression of visual field loss, in order to inform clinical practice (<LINK REF="REF-Osborne-2009" TYPE="REFERENCE">Osborne 2009</LINK>). Further efforts should be directed towards investigating long-term visual field preservation with neuroprotective drugs, since OAG is a chronic, progressive disease.</P>
<P>Another complication in studying the clinical efficacy of neuroprotective agents for glaucoma is that current methodologies used to detect RGC death may not be sufficiently sensitive to show the effect of neuroprotection. Perhaps the ability to prove the efficacy of a neuroprotective drug will depend on the ability to develop and validate new endpoints related to quantitative morphological methods of assessing the retinal ganglion cell layer. The use of sophisticated optical instrumentation and new methodologies to detect cellular events early in the disease process, such as real-time in vivo imaging of an apoptotic event (known as detection of apoptosing retinal cell, or DARC), may be useful quantitative measurements to assess neuroprotection in people with glaucoma.</P>
<P>As intraocular pressure (IOP) remains a standard measure in glaucoma research, the reasons for and considerations of the variation of IOP should be investigated. For example, one study showed that brimonidine may increase retinal blood flow while reclining, which could affect retinal blood flow autoregulation in OAG (<LINK REF="REF-Feke-2008" TYPE="REFERENCE">Feke 2008</LINK>). Evaluating the systemic effects of neuroprotective agents and the role they may play in clinical efficacy and basic mechanisms of action would allow us to determine whether neuroprotection is independent of IOP.</P>
<P>Additionally, in light of the non-significant findings reported from an expensive and time-consuming phase III trial of memantine, it is doubtful whether another long-term randomized controlled trial on neuroprotection will be undertaken in the absence of promising results from other sources. Futility trials, which are designed to eliminate ineffective interventions from development rather than determine whether interventions work, have been proposed for neuroprotection research in people with glaucoma (<LINK REF="REF-Quigley-2012" TYPE="REFERENCE">Quigley 2012</LINK>). Compared with the costs of large-scale (sample size of thousands), long-term (three to five years) randomized controlled trials, futility trials could be done with fewer participants and shorter follow-up periods. Quigley estimated that a futility trial for a neuroprotective agent for glaucoma could be done with fewer than 100 participants followed for two years (<LINK REF="REF-Quigley-2012" TYPE="REFERENCE">Quigley 2012</LINK>). Any neuroprotective agent found not to be futile could then be tested in a phase III randomized controlled trial.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-01-13 05:10:13 +0000" MODIFIED_BY="[Empty name]">
<P>We thank Dr Roberta Scherer, Dr Jayter Silva de Paula, and Dr Maria de Lourdes Veronesse Rodrigues for their comments on this review. We also acknowledge Chris Khanoyan and Yuanxi Jia for their assistance with the preparation of this review update. We thank Iris Gordon for creating and executing the search strategies and Nancy Fitton and Sarah Money for editing the Plain Language Summary.</P>
<P>We acknowledge Kanchan Ramchand for contributions to the first publication of this review (<LINK REF="REF-Sena-2010" TYPE="REFERENCE">Sena 2010</LINK>).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-12-01 18:19:25 +0000" MODIFIED_BY="[Empty name]">
<P>DS: none known.<BR/>KL: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-01-17 17:01:40 +0000" MODIFIED_BY="Anupa Shah">
<SUBSECTION>
<HEADING LEVEL="2">First publication of review (2010)</HEADING>
<P>Conceiving the review: DS<BR/>Designing the review: DS, Kanchan Ramchand<BR/>Co-ordinating the review: DS</P>
<P>Data collection for the review</P>
<UL>
<LI>Designing and undertaking electronic search strategies: Cochrane Eyes and Vision Group</LI>
<LI>Screening search results: DS, Kanchan Ramchand</LI>
<LI>Organizing retrieval of papers: DS, KL</LI>
<LI>Screening retrieved papers against inclusion criteria: DS, Kanchan Ramchand, KL</LI>
<LI>Providing additional data about papers: DS</LI>
<LI>Obtaining and screening data on unpublished studies: DS, KL</LI>
</UL>
<P>Data management for the review: DS, KL<BR/>Analysis of data: DS, KL<BR/>Writing the review: DS, KL</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Update of review (2017)</HEADING>
<P>Data collection for the review</P>
<UL>
<LI>Designing and undertaking electronic search strategies: Iris Gordon, Cochrane Eyes and Vision Information Specialist</LI>
<LI>Screening search results: DS, KL</LI>
<LI>Organizing retrieval of papers: KL</LI>
<LI>Screening retrieved papers against inclusion criteria: DS, KL</LI>
<LI>Providing additional data about papers: DS</LI>
</UL>
<P>Data management for the review: DS, KL<BR/>Analysis of data: DS, KL<BR/>Writing the review: DS, KL</P>
</SUBSECTION>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-01-13 05:22:09 +0000" MODIFIED_BY="[Empty name]">
<P>In the protocol and first published version of this review (<LINK REF="REF-Sena-2007" TYPE="REFERENCE">Sena 2007</LINK>; <LINK REF="REF-Sena-2010" TYPE="REFERENCE">Sena 2010</LINK>), we stated the minimum follow-up period for eligible studies to be five years. When updating the review in 2012, we modified the minimum follow-up period to be four years (<LINK REF="REF-Sena-2013" TYPE="REFERENCE">Sena 2013</LINK>).</P>
<P>For this update, we included a 'Summary of findings' table and GRADE assessments in accordance with Cochrane standards. We also modified the outcomes to better represent current methods for visual acuity measurements and comparative effective research. Specifically, we changed the visual acuity outcome from the proportion of participants in each Snellen category to the proportion of participants with loss of two or more lines of visual acuity measured by LogMAR chart. We also considered differences between the treated group of participants that developed progressive visual field loss and the untreated group of participants that developed progressive visual field loss as a subgroup rather than as part of the main analyses.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2017-01-13 05:23:51 +0000" MODIFIED_BY="[Empty name]">
<P>As of Issue 2, 2010 of the Cochrane Library<I>:</I>
</P>
<UL>
<LI>this review replaced the published review: Sycha T, Vass C, Findl O, Bauer P, Groke I, Schmetterer L, et al. Interventions for normal tension glaucoma. Cochrane Database of Systematic Reviews 2003, Issue 1;</LI>
<LI>the review by Sycha and colleagues was withdrawn from publication in the Cochrane Database of Systematic Reviews<I>.</I>
</LI>
</UL>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-01-17 17:07:24 +0000" MODIFIED_BY="Anupa Shah">
<STUDIES MODIFIED="2017-01-13 15:04:30 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2017-01-13 15:03:31 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-LoGTS-2011" MODIFIED="2017-01-13 15:03:31 +0000" MODIFIED_BY="[Empty name]" NAME="LoGTS 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-01-13 15:03:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garudadri CS, Choudhari NS, Rao HL, Senthil S</AU>
<TI>A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-pressure Glaucoma Treatment Study</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2011</YR>
<VL>152</VL>
<NO>5</NO>
<PG>877-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852598"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-01-13 15:03:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S; Low-Pressure Glaucoma Study Group</AU>
<TI>A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2011</YR>
<VL>151</VL>
<NO>4</NO>
<PG>671-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852599"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-12-05 11:54:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krupin T, Liebmann JM, Greenfield DS, Rosenberg LF, Ritch R, Yang JW</AU>
<TI>The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients</TI>
<SO>Ophthalmology</SO>
<YR>2005</YR>
<VL>112</VL>
<NO>3</NO>
<PG>376-85</PG>
<IDENTIFIERS MODIFIED="2012-12-05 11:54:22 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852600"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-20 20:53:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krupin T</AU>
<TI>A clinical trial studying neuroprotection in low-pressure glaucoma</TI>
<SO>Eye</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>Suppl 1</NO>
<PG>S51-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852601"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-20 20:53:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krupin T</AU>
<TI>Special considerations in low-tension glaucoma</TI>
<SO>Canadian Journal of Ophthalmology</SO>
<YR>2007</YR>
<VL>42</VL>
<NO>3</NO>
<PG>414-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852602"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-01-13 15:03:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quaranta L, Floriani I</AU>
<TI>The rate of progression and ocular perfusion pressure in the Low-pressure Glaucoma Treatment Study</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2011</YR>
<VL>152</VL>
<NO>5</NO>
<PG>880-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852603"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-09 20:43:26 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852597"/><IDENTIFIER MODIFIED="2012-07-09 20:43:26 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00317577"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-01-13 15:04:30 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alm-2004" MODIFIED="2009-01-19 15:38:49 +0000" MODIFIED_BY=" Iris Gordon" NAME="Alm 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-19 15:38:49 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alm A, Schoenfelder J, McDermott J</AU>
<TI>A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2004</YR>
<VL>122</VL>
<NO>7</NO>
<PG>957-65</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852605"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852604"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-2003" MODIFIED="2017-01-13 07:38:24 +0000" MODIFIED_BY="[Empty name]" NAME="Anderson 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-01-13 07:38:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson DR, Drance SM, Schulzer M; Collaborative Normal-Tension Glaucoma Study Group</AU>
<TI>Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2003</YR>
<VL>136</VL>
<NO>5</NO>
<PG>820-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852607"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852606"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Araie-2010" MODIFIED="2017-01-13 15:03:36 +0000" MODIFIED_BY="[Empty name]" NAME="Araie 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-01-13 15:03:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Araie M, Shirato S, Yamazaki Y, Kitazawa Y, Ohashi Y; Nipradilol-Timolol Study Group</AU>
<TI>Visual field loss in patients with normal-tension glaucoma under topical nipradilol or timolol: subgroup and subfield analyses of the nipradilol-timolol study</TI>
<SO>Japanese Journal of Ophthalmology</SO>
<YR>2010</YR>
<VL>54</VL>
<NO>4</NO>
<PG>278-85</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852609"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-01 17:24:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Araie M, Shirato S, Yamazaki Y, Matsumoto C, Kitazawa Y, Ohashi Y</AU>
<TI>Risk factors for progression of normal-tension glaucoma under &#946;-blocker monotherapy</TI>
<SO>Acta Ophthalmologica</SO>
<YR>2012</YR>
<VL>90</VL>
<NO>5</NO>
<PG>337-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4781028"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852608"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Araie-2011a" MODIFIED="2017-01-13 15:03:39 +0000" MODIFIED_BY="[Empty name]" NAME="Araie 2011a" YEAR="2011">
<REFERENCE MODIFIED="2017-01-13 15:03:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Araie M</AU>
<TI>Basic and clinical studies of pressure-independent damaging factors of open angle glaucoma</TI>
<SO>Nippon Ganka Gakkai Zasshi</SO>
<YR>2011</YR>
<VL>115</VL>
<NO>3</NO>
<PG>213-36</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852611"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852610"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Araie-2011b" MODIFIED="2017-01-13 15:03:43 +0000" MODIFIED_BY="[Empty name]" NAME="Araie 2011b" YEAR="2011">
<REFERENCE MODIFIED="2017-01-13 15:03:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Araie M, Mayama C</AU>
<TI>Use of calcium channel blockers for glaucoma</TI>
<SO>Progress in Retinal and Eye Research</SO>
<YR>2011</YR>
<VL>30</VL>
<NO>1</NO>
<PG>54-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852613"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852612"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blumenthal-2001" MODIFIED="2008-05-30 16:36:36 +0100" MODIFIED_BY="[Empty name]" NAME="Blumenthal 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-05-30 16:36:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blumenthal EZ, Weinreb RN</AU>
<TI>Assessment of the retinal nerve fiber layer in clinical trials of glaucoma neuroprotection</TI>
<SO>Survey of Ophthalmology</SO>
<YR>2001</YR>
<VL>45</VL>
<NO>Suppl 3</NO>
<PG>S305-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852615"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852614"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cantor-1997" MODIFIED="2009-01-19 15:49:45 +0000" MODIFIED_BY=" Iris Gordon" NAME="Cantor 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-01-19 15:49:45 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cantor LB, Burke J</AU>
<TI>Brimonidine</TI>
<SO>Expert Opinion on Investigational Drugs</SO>
<YR>1997</YR>
<VL>6</VL>
<NO>8</NO>
<PG>1063-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852617"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852616"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cellini-1999" MODIFIED="2012-12-05 13:04:40 +0000" MODIFIED_BY=" Iris Gordon" NAME="Cellini 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-12-05 13:04:40 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cellini M, Rossi A, Moretti M</AU>
<TI>The use of polyunsaturated fatty acids in ocular hypertension. A study with blue-on-yellow perimetry</TI>
<SO>Acta Ophthalmologica Scandinavica Supplement</SO>
<YR>1999</YR>
<VL>77</VL>
<NO>229</NO>
<PG>54-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852619"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852618"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chader-2012" MODIFIED="2017-01-13 07:52:02 +0000" MODIFIED_BY="[Empty name]" NAME="Chader 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-01-13 07:52:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chader GJ</AU>
<TI>Advances in glaucoma treatment and management: neurotrophic agents</TI>
<SO>Investigative Ophthalmology &amp; Visual Science</SO>
<YR>2012</YR>
<VL>53</VL>
<NO>5</NO>
<PG>2501-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852621"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852620"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Changhua-2003" MODIFIED="2009-01-19 15:56:10 +0000" MODIFIED_BY=" Iris Gordon" NAME="Changhua 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-19 15:56:10 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Changhua Y, Youqin J</AU>
<TI>A clinical study of the neuroprotection effect of Erigeron Breviscapus Hand-Mazz on glaucomatous patient eyes</TI>
<SO>Chinese Ophthalmic Research</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>3</NO>
<PG>307-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852623"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852622"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2006" MODIFIED="2009-01-19 15:56:46 +0000" MODIFIED_BY=" Iris Gordon" NAME="Chen 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-01-19 15:56:46 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen CL, Tseng HY, Wu KY</AU>
<TI>Rescula as an alternative therapy for beta-blockers with long-term drift effect in glaucoma patients</TI>
<SO>Kaohsiung Journal of Medical Sciences</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>6</NO>
<PG>266-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852625"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852624"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cho-2010" MODIFIED="2017-01-13 15:03:48 +0000" MODIFIED_BY="[Empty name]" NAME="Cho 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-01-13 15:03:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cho SW, Kim JM, Park KH, Choi CY</AU>
<TI>Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma</TI>
<SO>Japanese Journal of Ophthalmology</SO>
<YR>2010</YR>
<VL>54</VL>
<NO>5</NO>
<PG>407-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852627"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852626"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CNTGS-1998" MODIFIED="2017-01-13 07:37:07 +0000" MODIFIED_BY="[Empty name]" NAME="CNTGS 1998" YEAR="1998">
<REFERENCE MODIFIED="2017-01-13 07:37:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson DR, Drance SM, Schulzer M; Collaborative Normal-Tension Glaucoma Study Group</AU>
<TI>Natural history of normal-tension glaucoma</TI>
<SO>Ophthalmology</SO>
<YR>2001</YR>
<VL>108</VL>
<NO>2</NO>
<PG>247-53</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852629"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-10 14:46:50 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collaborative Normal-Tension Glaucoma Study Group</AU>
<TI>Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1998</YR>
<VL>126</VL>
<NO>4</NO>
<PG>487-97</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852630"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-10 14:47:04 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collaborative Normal-Tension Glaucoma Study Group</AU>
<TI>The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1998</YR>
<VL>126</VL>
<NO>4</NO>
<PG>498-505</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852631"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852628"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2005" MODIFIED="2008-05-30 17:11:23 +0100" MODIFIED_BY="[Empty name]" NAME="Cohen 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-05-30 17:11:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen JS, Khatana AK, Greff LJ</AU>
<TI>Evolving paradigms in the medical treatment of glaucoma</TI>
<SO>International Ophthalmology</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>5-6</NO>
<PG>253-65</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852633"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852632"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cordeiro-2011" MODIFIED="2017-01-13 15:03:54 +0000" MODIFIED_BY="[Empty name]" NAME="Cordeiro 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-01-13 15:03:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cordeiro MF, Levin LA</AU>
<TI>Clinical evidence for neuroprotection in glaucoma</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2011</YR>
<VL>152</VL>
<NO>5</NO>
<PG>715-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852635"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852634"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Costagliola-2014" MODIFIED="2016-12-01 16:38:38 +0000" MODIFIED_BY="[Empty name]" NAME="Costagliola 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-12-01 16:38:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costagliola C, Romano MR, dell'Omo R, Russo A, Mastropasqua R, Semeraro F</AU>
<TI>Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients: results of an open-label six-month follow-up</TI>
<SO>Journal of Medicinal Food</SO>
<YR>2014</YR>
<VL>17</VL>
<NO>9</NO>
<PG>949-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4781030"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4781029"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Danesh_x002d_Meyer-2011" MODIFIED="2017-01-13 15:03:58 +0000" MODIFIED_BY="[Empty name]" NAME="Danesh-Meyer 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-01-13 15:03:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Danesh-Meyer HV</AU>
<TI>Neuroprotection in glaucoma: recent and future directions</TI>
<SO>Current Opinion in Ophthalmology</SO>
<YR>2011</YR>
<VL>22</VL>
<NO>2</NO>
<PG>78-86</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852637"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852636"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drance-1998" MODIFIED="2012-12-05 15:51:45 +0000" MODIFIED_BY=" Iris Gordon" NAME="Drance 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-12-05 15:51:45 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drance SM</AU>
<TI>A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma</TI>
<SO>Journal of Glaucoma</SO>
<YR>1998</YR>
<VL>7</VL>
<NO>4</NO>
<PG>247-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852639"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852638"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EMGT-2002" MODIFIED="2012-12-05 15:54:55 +0000" MODIFIED_BY=" Iris Gordon" NAME="EMGT 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-12-05 15:53:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Erb C</AU>
<TI>Early Manifest Glaucoma Trial update 2004</TI>
<SO>Der Ophthalmologe</SO>
<YR>2005</YR>
<VL>102</VL>
<NO>3</NO>
<PG>219-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852641"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-12-05 15:53:44 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, et al</AU>
<TI>Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2002</YR>
<VL>120</VL>
<NO>10</NO>
<PG>1268-79</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852642"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-12-05 15:54:55 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E, et al</AU>
<TI>Factors for glaucoma progression and the effect of treatment</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2003</YR>
<VL>121</VL>
<NO>1</NO>
<PG>48-56</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852643"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852640"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eren-2012" MODIFIED="2016-12-01 16:40:55 +0000" MODIFIED_BY="[Empty name]" NAME="Eren 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-12-01 16:40:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eren MH, Gungel H, Altan C, Pasaoglu IB, Sabanci S</AU>
<TI>Comparison of dorzolamide/timolol and latanoprost/timolol fixed combinations on diurnal intraocular pressure control in primary open-angle glaucoma</TI>
<SO>Journal of Ocular Pharmacology and Therapeutics</SO>
<YR>2012</YR>
<VL>28</VL>
<NO>4</NO>
<PG>381-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4781032"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4781031"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Erichev-2016" MODIFIED="2016-12-01 16:56:39 +0000" MODIFIED_BY="[Empty name]" NAME="Erichev 2016" YEAR="2016">
<REFERENCE MODIFIED="2016-12-01 16:56:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Erichev VP, Mazurova YV, Dan T</AU>
<TI>Centrally acting cholinomimetics in the complex therapy of progressive glaucomatous optic neuropathy</TI>
<SO>Vestnik Oftalmologii</SO>
<YR>2016</YR>
<VL>132</VL>
<NO>2</NO>
<PG>33-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4781034"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4781033"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-2003" MODIFIED="2017-01-13 15:04:07 +0000" MODIFIED_BY="[Empty name]" NAME="Evans 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-01-13 15:04:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bartlett JD, Evans DW</AU>
<TI>Contrast sensitivity improvements in brimonidine-treated primary open-angle glaucoma patients suggest a neuroprotective mechanism</TI>
<SO>Investigative Ophthalmology &amp; Visual Science</SO>
<YR>2002</YR>
<VL>43</VL>
<PG>ARVO E-abstract 2201</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852645"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-12-05 15:55:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Evans DW, Hosking SL, Gherghel D, Bartlett JD</AU>
<TI>Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2003</YR>
<VL>87</VL>
<NO>12</NO>
<PG>1463-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852646"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852644"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frolov-2011" MODIFIED="2017-01-13 15:04:13 +0000" MODIFIED_BY="[Empty name]" NAME="Frolov 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-01-13 15:04:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frolov MA, Gonchar PA, Barashkov VI, Kumar V, Morozova NS, Frolov AM, et al</AU>
<TI>The effect of parenteral citicoline on visual functions and life quality of patients with primary open-angle glaucoma</TI>
<SO>Vestnik Oftalmologii</SO>
<YR>2011</YR>
<VL>127</VL>
<NO>5</NO>
<PG>18-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852648"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852647"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gandolfi-2004" MODIFIED="2017-01-13 15:04:17 +0000" MODIFIED_BY="[Empty name]" NAME="Gandolfi 2004" YEAR="2004">
<REFERENCE MODIFIED="2017-01-13 15:04:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gandolfi SA, Sangermani C, Cimino L, Ungaro N, Tardini M, Viswanathan A, et al</AU>
<TI>Is there a non IOP-related effect of brimonidine on visual field progression in human glaucoma?</TI>
<SO>Investigative Ophthalmology &amp; Visual Science</SO>
<YR>2004</YR>
<VL>45</VL>
<PG>ARVO E-abstract 2298</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852650"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852649"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia_x002d_Medina-2015" MODIFIED="2017-01-13 15:04:20 +0000" MODIFIED_BY="[Empty name]" NAME="Garcia-Medina 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-12-01 16:43:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Medina JJ, Garcia-Medina M, Garrido-Fernandez P, Galvan-Espinosa J, Garcia-Maturana C, Zanon-Moreno V, et al</AU>
<TI>A two-year follow-up of oral antioxidant supplementation in primary open-angle glaucoma: An open-label, randomized, controlled trial</TI>
<SO>Acta Ophthalmologica</SO>
<YR>2015</YR>
<VL>93</VL>
<NO>6</NO>
<PG>546-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4781035"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-01-13 15:04:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Medina JJ, Garcia-Medina M, Garrido-Fernandez P, Galvan-Espinosa J</AU>
<TI>A 2-year follow-up of antioxidant supplementation in primary open-angle glaucoma</TI>
<SO>Ophthalmic Research</SO>
<YR>2011</YR>
<VL>46</VL>
<NO>4</NO>
<PG>238</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852652"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852651"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ge-2008" MODIFIED="2017-01-13 15:02:40 +0000" MODIFIED_BY="[Empty name]" NAME="Ge 2008" YEAR="2008">
<REFERENCE MODIFIED="2017-01-13 15:02:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ge J</AU>
<TI>Glaucoma neuroprotection&#8212;how far is it from a dream to reality</TI>
<SO>Chung-Hua Yen Ko Tsa Chih (Chinese Journal of Ophthalmology)</SO>
<YR>2008</YR>
<VL>44</VL>
<NO>5</NO>
<PG>385-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852654"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852653"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-2014" MODIFIED="2017-01-13 07:51:25 +0000" MODIFIED_BY="[Empty name]" NAME="Guo 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-01-13 07:51:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo X, He M, Patel M, Congdon NG</AU>
<TI>Author response: Ginkgo biloba extract improves visual field damage in some patients affected by normal-tension glaucoma</TI>
<SO>Investigative Ophthalmology &amp; Visual Science</SO>
<YR>2014</YR>
<VL>55</VL>
<NO>4</NO>
<PG>2418</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4781037"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-01 16:58:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Guo X, Kong X, Huang R, Jin L, Ding X, He M, et al</AU>
<TI>Effect of Ginkgo biloba on visual field and contrast sensitivity in Chinese patients with normal tension glaucoma: a randomized, crossover clinical trial</TI>
<SO>Investigative Ophthalmology &amp; Visual Science</SO>
<YR>2014</YR>
<VL>55</VL>
<NO>1</NO>
<PG>110-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4781038"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4781036"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-1995" MODIFIED="2009-01-19 16:17:36 +0000" MODIFIED_BY=" Iris Gordon" NAME="Harris 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-01-19 16:17:36 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harris A, Spaeth GL, Sergott RC, Katz LJ, Cantor LB, Martin BJ</AU>
<TI>Retrobulbar arterial hemodynamic effects of betaxolol and timolol in normal-tension glaucoma</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1995</YR>
<VL>120</VL>
<NO>2</NO>
<PG>168-75</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852656"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852655"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-1999" MODIFIED="2012-12-05 16:12:31 +0000" MODIFIED_BY="[Empty name]" NAME="Harris 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-12-05 16:12:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harris A, Arend O, Kagemann L, Garrett M, Chung HS, Martin B</AU>
<TI>Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma</TI>
<SO>Journal of Ocular Pharmacology and Therapeutics</SO>
<YR>1999</YR>
<VL>15</VL>
<NO>3</NO>
<PG>189-97</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852658"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852657"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoyng-2002" MODIFIED="2009-01-19 16:34:07 +0000" MODIFIED_BY=" Iris Gordon" NAME="Hoyng 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-01-19 16:34:07 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoyng PF, Kitazawa Y</AU>
<TI>Medical treatment of normal tension glaucoma</TI>
<SO>Survey of Ophthalmology</SO>
<YR>2002</YR>
<VL>47</VL>
<NO>Suppl 1</NO>
<PG>S116-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852660"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852659"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iester-2004" MODIFIED="2017-01-13 07:54:05 +0000" MODIFIED_BY="[Empty name]" NAME="Iester 2004" YEAR="2004">
<REFERENCE MODIFIED="2017-01-13 07:54:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iester M, Perdicchi A, Venturino G, Rolando M, Traverso CE, Leonardi E, et al</AU>
<TI>Short-term effects of Bimatoprost in glaucoma patients from an outpatient clinic</TI>
<SO>Journal of Ocular Pharmacology and Therapeutics</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>5</NO>
<PG>393-400</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852662"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852661"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inan-2003" MODIFIED="2009-01-19 16:37:22 +0000" MODIFIED_BY=" Iris Gordon" NAME="Inan 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-19 16:37:22 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inan UU, Ermis SS, Yucel A, Ozturk F</AU>
<TI>The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial</TI>
<SO>Acta Ophthalmologica Scandinavica</SO>
<YR>2003</YR>
<VL>81</VL>
<NO>2</NO>
<PG>155-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852664"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852663"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kass-1989" MODIFIED="2009-01-19 16:40:01 +0000" MODIFIED_BY=" Iris Gordon" NAME="Kass 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-01-19 16:40:01 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kass MA</AU>
<TI>Timolol treatment prevents or delays glaucomatous visual field loss in individuals with ocular hypertension: a five-year, randomized, double-masked, clinical trial</TI>
<SO>Transactions of the American Ophthalmological Society</SO>
<YR>1989</YR>
<VL>87</VL>
<PG>598-618</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852666"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852665"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kjellgren-1995" MODIFIED="2009-01-19 16:43:07 +0000" MODIFIED_BY=" Iris Gordon" NAME="Kjellgren 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-01-19 16:43:07 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kjellgren D, Douglas G, Mikelberg FS, Drance SM, Alm A</AU>
<TI>The short-time effect of latanoprost on the intraocular pressure in normal pressure glaucoma</TI>
<SO>Acta Ophthalmologica Scandinavica</SO>
<YR>1995</YR>
<VL>73</VL>
<NO>3</NO>
<PG>233-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852668"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852667"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koseki-1999" MODIFIED="2009-01-19 16:45:05 +0000" MODIFIED_BY=" Iris Gordon" NAME="Koseki 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-01-19 16:45:05 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koseki N, Araie M, Yamagami J, Shirato S, Yamamoto S</AU>
<TI>Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure</TI>
<SO>Journal of Glaucoma</SO>
<YR>1999</YR>
<VL>8</VL>
<NO>2</NO>
<PG>117-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852670"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852669"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2002" MODIFIED="2008-05-23 16:54:07 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-05-23 16:54:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu CJ, Ko YC, Cheng CY, Chiu AW, Chou JC, Hsu WM, et al</AU>
<TI>Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients</TI>
<SO>Ophthalmology</SO>
<YR>2002</YR>
<VL>109</VL>
<NO>12</NO>
<PG>2241-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852672"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852671"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2012" MODIFIED="2016-12-01 16:48:03 +0000" MODIFIED_BY="[Empty name]" NAME="Ma 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-12-01 16:48:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma EP, Zhao XZ, Liu SB, Dong L, Zeng ZN</AU>
<TI>Clinical observation of PNT in treatment of primary open angle glaucoma and ocular hypertension</TI>
<SO>International Eye Science</SO>
<YR>2012</YR>
<VL>12</VL>
<NO>9</NO>
<PG>1666-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4781040"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4781039"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mastropasqua-1998" MODIFIED="2008-05-23 16:56:22 +0100" MODIFIED_BY="[Empty name]" NAME="Mastropasqua 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-05-23 16:56:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mastropasqua L, Ciancaglini M, Carpineto P, Verdesca G, Ciafre M, Costagliola C</AU>
<TI>The effect of 1% apraclonidine on visual field parameters in patients with glaucoma and ocular hypertension</TI>
<SO>Annals of Ophthalmology-Glaucoma</SO>
<YR>1998</YR>
<VL>30</VL>
<NO>1</NO>
<PG>41-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852674"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852673"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCarty-2003" MODIFIED="2009-01-19 17:04:26 +0000" MODIFIED_BY=" Iris Gordon" NAME="McCarty 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-19 17:04:26 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCarty TM, Hardten DR, Anderson NJ, Rosheim K, Samuelson TW</AU>
<TI>Evaluation of neuroprotective qualities of brimonidine during LASIK</TI>
<SO>Ophthalmology</SO>
<YR>2003</YR>
<VL>110</VL>
<NO>8</NO>
<PG>1615-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852676"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852675"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Donoghue-2000" MODIFIED="2017-01-13 07:58:54 +0000" MODIFIED_BY="[Empty name]" NAME="O'Donoghue 2000" YEAR="2000">
<REFERENCE MODIFIED="2017-01-13 07:58:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Donoghue EP; the UK and Ireland Latanoprost Study Group</AU>
<TI>A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2000</YR>
<VL>84</VL>
<NO>6</NO>
<PG>579-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852678"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852677"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Park-2011" MODIFIED="2017-01-13 15:04:30 +0000" MODIFIED_BY="[Empty name]" NAME="Park 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-01-13 15:04:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Park JW, Kwon HJ, Chung WS, Kim CY, Seong GJ</AU>
<TI>Short-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma</TI>
<SO>Korean Journal of Ophthalmology</SO>
<YR>2011</YR>
<VL>25</VL>
<NO>5</NO>
<PG>323-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852680"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852679"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pfeiffer-2002" MODIFIED="2012-12-05 16:25:54 +0000" MODIFIED_BY="[Empty name]" NAME="Pfeiffer 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-12-05 16:25:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pfeiffer N</AU>
<TI>A comparison of the fixed combination of latanoprost and timolol with its individual components</TI>
<SO>Graefes Archive for Clinical and Experimental Ophthalmology</SO>
<YR>2002</YR>
<VL>240</VL>
<NO>11</NO>
<PG>893-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852682"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852681"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roberti-2014" MODIFIED="2017-01-13 08:00:19 +0000" MODIFIED_BY="[Empty name]" NAME="Roberti 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-01-13 08:00:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberti G, Tanga L, Parisi V, Sampalmieri M, Centofanti M, Manni G</AU>
<TI>A preliminary study of the neuroprotective role of citicoline eye drops in glaucomatous optic neuropathy</TI>
<SO>Indian Journal of Ophthalmology</SO>
<YR>2014</YR>
<VL>62</VL>
<NO>5</NO>
<PG>549-53</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4781042"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4781041"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robin-1993" MODIFIED="2008-05-23 17:14:43 +0100" MODIFIED_BY="[Empty name]" NAME="Robin 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-05-23 17:14:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robin AL</AU>
<TI>Effect of topical apraclonidine on the frequency of intraocular pressure elevations after combined extracapsular cataract extraction and trabeculectomy</TI>
<SO>Ophthalmology</SO>
<YR>1993</YR>
<VL>100</VL>
<NO>5</NO>
<PG>628-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852684"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852683"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rulo-1996" MODIFIED="2008-06-02 17:19:14 +0100" MODIFIED_BY="[Empty name]" NAME="Rulo 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-06-02 17:19:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rulo AH, Greve EL, Geijssen HC, Hoyng PF</AU>
<TI>Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma</TI>
<SO>Ophthalmology</SO>
<YR>1996</YR>
<VL>103</VL>
<NO>8</NO>
<PG>1276-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852686"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852685"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sari-2016" MODIFIED="2016-12-01 16:55:29 +0000" MODIFIED_BY="[Empty name]" NAME="Sari 2016" YEAR="2016">
<REFERENCE MODIFIED="2016-12-01 16:55:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sari MD, Sihotang AD, Lelo A</AU>
<TI>Ginkgo biloba extract effect on oxidative stress marker malonildialdehyde, redox enzyme gluthation peroxidase, visual field damage, and retinal nerve fiber layer thickness in primary open angle glaucoma</TI>
<SO>International Journal of PharmTech Research</SO>
<YR>2016</YR>
<VL>9</VL>
<NO>3</NO>
<PG>158-66</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4781044"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4781043"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sawada-1996" MODIFIED="2009-01-19 17:25:35 +0000" MODIFIED_BY=" Iris Gordon" NAME="Sawada 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-01-19 17:25:35 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sawada A, Kitazawa Y, Yamamoto T, Okabe I, Ichien K</AU>
<TI>Prevention of visual field defect progression with Brovincamine in eyes with normal-tension glaucoma</TI>
<SO>Ophthalmology</SO>
<YR>1996</YR>
<VL>103</VL>
<NO>2</NO>
<PG>283-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852688"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852687"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2010" MODIFIED="2012-12-05 16:35:59 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-12-05 16:35:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y, Qiu B, Zhang CX, Ou Y, Pang L, Li Z</AU>
<TI>Neuro-protective effects of yiyanming solution on visual function of glaucoma patient</TI>
<SO>Chinese Ophthalmic Research</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>11</NO>
<PG>1087-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852690"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852689"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2015" MODIFIED="2016-12-02 21:39:05 +0000" MODIFIED_BY="[Empty name]" NAME="Wu 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-12-02 21:39:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu RY, Huang CQ, Lu JX, Hu QQ, Huang WY, Xu YZ</AU>
<TI>Preliminary clinical evaluation of nerve growth factor gel on neuroprotection in patients with glaucoma</TI>
<SO>International Eye Science</SO>
<YR>2015</YR>
<VL>15</VL>
<NO>2</NO>
<PG>255-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4781046"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4781045"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2017-01-13 15:00:50 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00141882" MODIFIED="2017-01-13 15:00:04 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00141882" YEAR="">
<REFERENCE MODIFIED="2017-01-13 14:59:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00141882</AU>
<TI>Memantine in patients with chronic glaucoma</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00141882</SO>
<YR>(date first received 31 August 2005)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852692"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-01-15 15:19:25 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852691"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00168350" MODIFIED="2017-01-13 15:00:50 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00168350" YEAR="2009">
<REFERENCE MODIFIED="2017-01-13 15:00:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00168350</AU>
<TI>Memantine in patients with chronic glaucoma</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00168350</SO>
<YR>(date first received 9 September 2005)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2852694"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-11-18 18:21:56 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2852693"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2008-12-02 19:38:13 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-01-13 15:01:43 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2017-01-13 15:01:43 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-AAO-Preferred-Practice-Pattern" MODIFIED="2017-01-13 08:08:44 +0000" MODIFIED_BY="[Empty name]" NAME="AAO Preferred Practice Pattern" TYPE="OTHER">
<AU>American Academy of Ophthalmology</AU>
<TI>Primary open-angle glaucoma, preferred practice pattern</TI>
<SO>www.aao.org/ppp</SO>
<YR>(accessed prior to 12 January 2017)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-AGIS-1994" NAME="AGIS 1994" TYPE="JOURNAL_ARTICLE">
<TI>Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability</TI>
<SO>Ophthalmology</SO>
<YR>1994</YR>
<VL>101</VL>
<NO>8</NO>
<PG>1445-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Armaly-1980" MODIFIED="2009-01-19 17:31:39 +0000" MODIFIED_BY=" Iris Gordon" NAME="Armaly 1980" TYPE="JOURNAL_ARTICLE">
<AU>Armaly MF, Krueger DE, Maunder L, Becker B, Hetherington J Jr, Kolker AE, et al</AU>
<TI>Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1980</YR>
<VL>98</VL>
<NO>12</NO>
<PG>2163-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bathija-1998" MODIFIED="2009-01-19 17:37:47 +0000" MODIFIED_BY=" Iris Gordon" NAME="Bathija 1998" TYPE="JOURNAL_ARTICLE">
<AU>Bathija R, Gupta N, Zangwill L, Weinreb RN</AU>
<TI>Changing definition of glaucoma</TI>
<SO>Journal of Glaucoma</SO>
<YR>1998</YR>
<VL>7</VL>
<NO>3</NO>
<PG>165-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonomi-2002" MODIFIED="2009-01-19 17:43:21 +0000" MODIFIED_BY=" Iris Gordon" NAME="Bonomi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bonomi L</AU>
<TI>Epidemiology of angle-closure glaucoma</TI>
<SO>Acta Ophthalmologica Scandinavica</SO>
<YR>2002</YR>
<VL>80</VL>
<NO>Suppl 236</NO>
<PG>11-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brubaker-1996" MODIFIED="2009-01-19 17:44:40 +0000" MODIFIED_BY=" Iris Gordon" NAME="Brubaker 1996" TYPE="JOURNAL_ARTICLE">
<AU>Brubaker RF</AU>
<TI>Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1996</YR>
<VL>121</VL>
<NO>5</NO>
<PG>473-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cheung-2008" MODIFIED="2012-12-05 16:44:34 +0000" MODIFIED_BY="[Empty name]" NAME="Cheung 2008" TYPE="JOURNAL_ARTICLE">
<AU>Cheung W, Guo L, Cordeiro MF</AU>
<TI>Neuroprotection in glaucoma: drug-based approaches</TI>
<SO>Optometry and Vision Science</SO>
<YR>2008</YR>
<VL>85</VL>
<NO>6</NO>
<PG>406-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cockburn-1983" MODIFIED="2009-01-19 17:46:29 +0000" MODIFIED_BY=" Iris Gordon" NAME="Cockburn 1983" TYPE="JOURNAL_ARTICLE">
<AU>Cockburn DM</AU>
<TI>Does reduction of intraocular pressure (IOP) prevent visual field loss in glaucoma?</TI>
<SO>American Journal of Optometry and Physiological Optics</SO>
<YR>1983</YR>
<VL>60</VL>
<NO>8</NO>
<PG>705-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Csaky-2008" MODIFIED="2012-12-05 16:45:07 +0000" MODIFIED_BY="[Empty name]" NAME="Csaky 2008" TYPE="JOURNAL_ARTICLE">
<AU>Csaky KG, Richman EA, Ferris FL 3rd</AU>
<TI>Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium</TI>
<SO>Investigative Ophthalmology and Visual Science</SO>
<YR>2008</YR>
<VL>49</VL>
<NO>2</NO>
<PG>479-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Danesh_x002d_Meyer-2009" MODIFIED="2010-01-15 13:13:33 +0000" MODIFIED_BY="[Empty name]" NAME="Danesh-Meyer 2009" TYPE="JOURNAL_ARTICLE">
<AU>Danesh-Meyer HV, Levin LA</AU>
<TI>Neuroprotection: extrapolating from neurologic diseases to the eye</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2009</YR>
<VL>148</VL>
<NO>2</NO>
<PG>186-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2016-12-13 11:19:32 +0000" MODIFIED_BY="[Empty name]" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JP, Altman DG editor(s)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fan-2010" MODIFIED="2012-08-13 15:23:40 +0100" MODIFIED_BY="[Empty name]" NAME="Fan 2010" TYPE="JOURNAL_ARTICLE">
<AU>Fan BJ, Figuieredo Sena DR, Pasquale LR, Grosskreutz CL, Rhee DJ, Chen TC, et al</AU>
<TI>Lack of association of polymorphisms in elastin with pseudoexfoliation syndrome and glaucoma</TI>
<SO>Journal of Glaucoma</SO>
<YR>2010</YR>
<VL>19</VL>
<NO>7</NO>
<PG>432-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feke-2008" MODIFIED="2012-08-13 15:30:44 +0100" MODIFIED_BY="[Empty name]" NAME="Feke 2008" TYPE="JOURNAL_ARTICLE">
<AU>Feke GT, Pasquale LR</AU>
<TI>Retinal blood flow response to posture change in glaucoma patients compared with healthy subjects</TI>
<SO>Ophthalmology</SO>
<YR>2008</YR>
<VL>115</VL>
<NO>2</NO>
<PG>246-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foster-2000" MODIFIED="2009-01-19 19:25:18 +0000" MODIFIED_BY=" Iris Gordon" NAME="Foster 2000" TYPE="JOURNAL_ARTICLE">
<AU>Foster PJ, Wong JS, Wong E, Chen FG, Machin D, Chew PT</AU>
<TI>Accuracy of clinical estimates of intraocular pressure in Chinese eyes</TI>
<SO>Ophthalmology</SO>
<YR>2000</YR>
<VL>107</VL>
<NO>10</NO>
<PG>1816-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Friedman-2004" MODIFIED="2012-12-05 17:09:33 +0000" MODIFIED_BY="[Empty name]" NAME="Friedman 2004" TYPE="JOURNAL_ARTICLE">
<AU>Friedman DS, Wolfs RC, O'Colmain BJ, Klein BE, Taylor HR, West S, et al</AU>
<TI>Prevalence of open-angle glaucoma among adults in the Unites States</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2004</YR>
<VL>122</VL>
<NO>4</NO>
<PG>532-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garway_x002d_Heath-1998" MODIFIED="2010-01-15 16:11:11 +0000" MODIFIED_BY="[Empty name]" NAME="Garway-Heath 1998" TYPE="JOURNAL_ARTICLE">
<AU>Garway-Heath DF, Ruben ST, Viswanathan A, Hitchings RA</AU>
<TI>Vertical cup/disc ratio in relation to optic disc size: its value in the assessment of the glaucoma suspect</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1998</YR>
<VL>82</VL>
<NO>10</NO>
<PG>1118-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glanville-2006" NAME="Glanville 2006" TYPE="JOURNAL_ARTICLE">
<AU>Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J</AU>
<TI>How to identify randomized controlled trials in MEDLINE: ten years on</TI>
<SO>Journal of the Medical Library Association</SO>
<YR>2006</YR>
<VL>94</VL>
<NO>2</NO>
<PG>130-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2014" MODIFIED="2016-12-13 11:35:15 +0000" MODIFIED_BY="[Empty name]" NAME="GRADEpro 2014" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro</TI>
<YR>2014</YR>
<EN>accessed 30 November 2016</EN>
<PB>GRADE Working Group, McMaster University</PB>
<CY>Hamilton (ON)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gupta-1997" MODIFIED="2009-01-19 19:28:50 +0000" MODIFIED_BY=" Iris Gordon" NAME="Gupta 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gupta N, Weinreb RN</AU>
<TI>New definitions of glaucoma</TI>
<SO>Current Opinion in Ophthalmology</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>2</NO>
<PG>38-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hare-2009" MODIFIED="2017-01-13 08:16:14 +0000" MODIFIED_BY="[Empty name]" NAME="Hare 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hare WA, Wheeler L</AU>
<TI>Experimental glutamatergic excitotoxicity in rabbit retinal ganglion cells: block by memantine</TI>
<SO>Investigative Ophthalmology &amp; Visual Science</SO>
<YR>2009</YR>
<VL>50</VL>
<NO>6</NO>
<PG>2940-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hauser-2006a" MODIFIED="2017-01-13 08:16:40 +0000" MODIFIED_BY="[Empty name]" NAME="Hauser 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Hauser MA, Allingham RR, Linkroum K, Wang J, LaRocque-Abramson K, Figueiredo D, et al</AU>
<TI>Distribution of WDR36 DNA sequence variants in patients with primary open-angle glaucoma</TI>
<SO>Investigative Ophthalmology &amp; Visual Science</SO>
<YR>2006</YR>
<VL>47</VL>
<NO>6</NO>
<PG>2542-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hauser-2006b" MODIFIED="2009-01-19 19:32:24 +0000" MODIFIED_BY=" Iris Gordon" NAME="Hauser 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Hauser MA, Sena DF, Flor J, Walter J, Auguste J, Larocque-Abramson K, et al</AU>
<TI>Distribution of optineurin sequence variations in an ethnically diverse population of low-tension glaucoma patients from the United States</TI>
<SO>Journal of Glaucoma</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>5</NO>
<PG>358-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heijl-2002" MODIFIED="2012-12-05 16:52:54 +0000" MODIFIED_BY=" Iris Gordon" NAME="Heijl 2002" TYPE="JOURNAL_ARTICLE">
<AU>Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, et al</AU>
<TI>Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2002</YR>
<VL>120</VL>
<NO>10</NO>
<PG>1268-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-12-13 11:20:49 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JP, Altman DG, Sterne JAC editor(s)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hunter-2005" MODIFIED="2009-01-19 19:36:02 +0000" MODIFIED_BY=" Iris Gordon" NAME="Hunter 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hunter DJ</AU>
<TI>Gene-environment interactions in human diseases</TI>
<SO>Nature Reviews Genetics</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>4</NO>
<PG>287-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ju-2009" MODIFIED="2017-01-13 08:19:21 +0000" MODIFIED_BY="[Empty name]" NAME="Ju 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ju WK, Kim KY, Angert M, Duong-Polk KX, Lindsey JD, Ellisman MH, et al</AU>
<TI>Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina</TI>
<SO>Investigative Ophthalmology &amp; Visual Science</SO>
<YR>2009</YR>
<VL>50</VL>
<NO>2</NO>
<PG>707-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kamal-1998" MODIFIED="2017-01-13 08:19:42 +0000" MODIFIED_BY="[Empty name]" NAME="Kamal 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kamal D, Hitchings R</AU>
<TI>Normal tension glaucoma&#8212;a practical approach</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1998</YR>
<VL>82</VL>
<NO>7</NO>
<PG>835-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levin-1999" MODIFIED="2009-01-19 19:39:14 +0000" MODIFIED_BY=" Iris Gordon" NAME="Levin 1999" TYPE="JOURNAL_ARTICLE">
<AU>Levin LA</AU>
<TI>Direct and indirect approaches to neuroprotective therapy of glaucomatous optic neuropathy</TI>
<SO>Survey of Ophthalmology</SO>
<YR>1999</YR>
<VL>43</VL>
<NO>Suppl 1</NO>
<PG>S98-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levin-2008" MODIFIED="2010-01-15 13:18:05 +0000" MODIFIED_BY="[Empty name]" NAME="Levin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Levin LA, Peeples P</AU>
<TI>History of neuroprotection and rationale as a therapy for glaucoma</TI>
<SO>American Journal of Managed Care</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>1 Suppl</NO>
<PG>S11-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lipton-2003" MODIFIED="2010-01-15 13:18:32 +0000" MODIFIED_BY="[Empty name]" NAME="Lipton 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lipton SA</AU>
<TI>Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage</TI>
<SO>Survey of Ophthalmology</SO>
<YR>2003</YR>
<VL>48</VL>
<NO>Suppl 1</NO>
<PG>S38-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McKinnon-2008" MODIFIED="2010-01-15 13:19:09 +0000" MODIFIED_BY="[Empty name]" NAME="McKinnon 2008" TYPE="JOURNAL_ARTICLE">
<AU>McKinnon SJ, Goldberg LD, Peeples P, Walt JG, Bramley TJ</AU>
<TI>Current management of glaucoma and the need for complete therapy</TI>
<SO>American Journal of Managed Care</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>1 Suppl</NO>
<PG>S20-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neacsu-2003" MODIFIED="2009-01-19 19:40:41 +0000" MODIFIED_BY=" Iris Gordon" NAME="Neacsu 2003" TYPE="JOURNAL_ARTICLE">
<AU>Neacsu A, Oprean C, Curea M, Tuchila G, Trifu M</AU>
<TI>Neuroprotection with carotenoids in glaucoma</TI>
<SO>Oftalmologia</SO>
<YR>2003</YR>
<VL>59</VL>
<NO>4</NO>
<PG>70-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neufeld-1997" MODIFIED="2009-01-19 19:42:28 +0000" MODIFIED_BY=" Iris Gordon" NAME="Neufeld 1997" TYPE="JOURNAL_ARTICLE">
<AU>Neufeld AH, Hernandez MR, Gonzalez M</AU>
<TI>Nitric oxide synthase in the human glaucomatous optic nerve head</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1997</YR>
<VL>115</VL>
<NO>4</NO>
<PG>497-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neufeld-1998" MODIFIED="2009-01-19 19:43:30 +0000" MODIFIED_BY=" Iris Gordon" NAME="Neufeld 1998" TYPE="JOURNAL_ARTICLE">
<AU>Neufeld AH</AU>
<TI>New conceptual approaches for pharmacological neuroprotection in glaucomatous neuronal degeneration</TI>
<SO>Journal of Glaucoma</SO>
<YR>1998</YR>
<VL>7</VL>
<NO>6</NO>
<PG>434-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-Guidelines" MODIFIED="2017-01-13 15:01:43 +0000" MODIFIED_BY="[Empty name]" NAME="NICE Guidelines" TYPE="OTHER">
<AU>National Collaborating Centre for Acute Care</AU>
<TI>Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension. National Institute for Health and Clinical Excellence guideline</TI>
<SO>www.nice.org.uk/guidance/cg85</SO>
<YR>(accessed 12 November 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nouri_x002d_Mahdavi-2004" NAME="Nouri-Mahdavi 2004" TYPE="JOURNAL_ARTICLE">
<AU>Nouri-Mahdavi K, Hoffman D, Coleman AL, Liu G, Li G, Gaasterland D, et al</AU>
<TI>Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study</TI>
<SO>Ophthalmology</SO>
<YR>2004</YR>
<VL>111</VL>
<NO>9</NO>
<PG>1627-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Osborne-2003" MODIFIED="2009-01-19 19:47:53 +0000" MODIFIED_BY=" Iris Gordon" NAME="Osborne 2003" TYPE="JOURNAL_ARTICLE">
<AU>Osborne NN, Chidlow G, Wood J, Casson R</AU>
<TI>Some current ideas on the pathogenesis and the role of neuroprotection in glaucomatous optic neuropathy</TI>
<SO>European Journal of Ophthalmology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>Suppl 3</NO>
<PG>S19-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Osborne-2009" MODIFIED="2010-01-15 13:23:25 +0000" MODIFIED_BY="[Empty name]" NAME="Osborne 2009" TYPE="JOURNAL_ARTICLE">
<AU>Osborne NN</AU>
<TI>Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned</TI>
<SO>Acta Ophthalmologica</SO>
<YR>2009</YR>
<VL>87</VL>
<NO>4</NO>
<PG>450-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quigley-1999" MODIFIED="2009-01-19 19:49:20 +0000" MODIFIED_BY=" Iris Gordon" NAME="Quigley 1999" TYPE="JOURNAL_ARTICLE">
<AU>Quigley HA</AU>
<TI>Neuronal death in glaucoma</TI>
<SO>Progress in Retinal and Eye Research</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>1</NO>
<PG>39-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quigley-2001" MODIFIED="2009-01-19 19:50:21 +0000" MODIFIED_BY=" Iris Gordon" NAME="Quigley 2001" TYPE="JOURNAL_ARTICLE">
<AU>Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R</AU>
<TI>The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2001</YR>
<VL>119</VL>
<NO>12</NO>
<PG>1819-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quigley-2006" MODIFIED="2010-01-15 13:21:43 +0000" MODIFIED_BY="[Empty name]" NAME="Quigley 2006" TYPE="JOURNAL_ARTICLE">
<AU>Quigley HA</AU>
<TI>Number of people with glaucoma worldwide in 2010 and 2020</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2006</YR>
<VL>90</VL>
<NO>3</NO>
<PG>262-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quigley-2012" MODIFIED="2012-10-26 14:03:51 +0100" MODIFIED_BY="[Empty name]" NAME="Quigley 2012" TYPE="JOURNAL_ARTICLE">
<AU>Quigley HA</AU>
<TI>Clinical trials for glaucoma neuroprotection are not impossible</TI>
<SO>Current Opinion in Ophthalmology</SO>
<YR>2012</YR>
<VL>23</VL>
<NO>2</NO>
<PG>144-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ramakrishnan-2003" MODIFIED="2009-01-19 19:52:57 +0000" MODIFIED_BY=" Iris Gordon" NAME="Ramakrishnan 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ramakrishnan R, Nirmalan PK, Krishnadas R, Thulasiraj RD, Tielsch JM, Katz J, et al</AU>
<TI>Glaucoma in a rural population of southern India: the Aravind comprehensive eye survey</TI>
<SO>Ophthalmology</SO>
<YR>2003</YR>
<VL>110</VL>
<NO>8</NO>
<PG>1484-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Resnikoff-2004" MODIFIED="2009-01-19 19:54:38 +0000" MODIFIED_BY=" Iris Gordon" NAME="Resnikoff 2004" TYPE="JOURNAL_ARTICLE">
<AU>Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al</AU>
<TI>Global data on visual impairment in the year 2002</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>2004</YR>
<VL>82</VL>
<NO>11</NO>
<PG>844-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2016-12-13 11:23:10 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwartz-1996" MODIFIED="2009-01-19 19:56:23 +0000" MODIFIED_BY=" Iris Gordon" NAME="Schwartz 1996" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz M, Belkin M, Yoles E, Solomon A</AU>
<TI>Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration</TI>
<SO>Journal of Glaucoma</SO>
<YR>1996</YR>
<VL>5</VL>
<NO>6</NO>
<PG>427-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwartz-2000" MODIFIED="2009-01-19 19:57:22 +0000" MODIFIED_BY=" Iris Gordon" NAME="Schwartz 2000" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz M, Yoles E</AU>
<TI>Neuroprotection: a new treatment modality for glaucoma?</TI>
<SO>Current Opinion in Ophthalmology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>2</NO>
<PG>107-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seong-2009" MODIFIED="2016-12-13 11:23:28 +0000" MODIFIED_BY="[Empty name]" NAME="Seong 2009" TYPE="JOURNAL_ARTICLE">
<AU>Seong GJ, Rho SH, Kim CS, Moon JI, Kook MS, Kim YY, et al</AU>
<TI>Potential benefit of intraocular pressure reduction in normal-tension glaucoma in South Korea</TI>
<SO>Journal of Ocular Pharmacology and Therapeutics</SO>
<YR>2009</YR>
<VL>25</VL>
<NO>1</NO>
<PG>91-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shields-1996" MODIFIED="2017-01-13 08:28:59 +0000" MODIFIED_BY="[Empty name]" NAME="Shields 1996" TYPE="BOOK_SECTION">
<AU>Shields MB, Ritch R, Krupin T</AU>
<TI>Classification of the glaucomas</TI>
<SO>The Glaucomas</SO>
<YR>1996</YR>
<EN>2nd</EN>
<ED>Ritch R, Shields MB, Krupin T</ED>
<PB>Mosby</PB>
<CY>St. Louis</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tielsch-1991" MODIFIED="2017-01-13 08:30:10 +0000" MODIFIED_BY="[Empty name]" NAME="Tielsch 1991" TYPE="JOURNAL_ARTICLE">
<AU>Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J</AU>
<TI>Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey</TI>
<SO>JAMA</SO>
<YR>1991</YR>
<VL>266</VL>
<NO>3</NO>
<PG>369-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vass-2007" MODIFIED="2017-01-13 08:30:27 +0000" MODIFIED_BY="[Empty name]" NAME="Vass 2007" TYPE="COCHRANE_REVIEW">
<AU>Vass C, Hirn C, Sycha T, Findl O, Sacu S, Bauer P, et al</AU>
<TI>Medical interventions for primary open angle glaucoma and ocular hypertension</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-07-25 20:18:05 +0100" MODIFIED_BY=" Iris Gordon"><IDENTIFIER MODIFIED="2012-07-25 20:18:05 +0100" MODIFIED_BY=" Iris Gordon" TYPE="DOI" VALUE="10.1002/14651858.CD003167.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weinreb-1999" MODIFIED="2009-01-19 20:18:03 +0000" MODIFIED_BY=" Iris Gordon" NAME="Weinreb 1999" TYPE="JOURNAL_ARTICLE">
<AU>Weinreb RN, Levin LA</AU>
<TI>Is neuroprotection a viable therapy for glaucoma?</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1998</YR>
<VL>117</VL>
<NO>11</NO>
<PG>1540-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhong-2007" MODIFIED="2017-01-13 08:31:04 +0000" MODIFIED_BY="[Empty name]" NAME="Zhong 2007" TYPE="JOURNAL_ARTICLE">
<AU>Zhong L, Bradley J, Schubert W, Ahmed E, Adamis AP, Shima DT, et al</AU>
<TI>Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice</TI>
<SO>Investigative Ophthalmology &amp; Visual Science</SO>
<YR>2007</YR>
<VL>48</VL>
<NO>3</NO>
<PG>1212-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-11-30 20:35:08 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Sena-2007" MODIFIED="2016-11-30 20:35:08 +0000" MODIFIED_BY="[Empty name]" NAME="Sena 2007" TYPE="COCHRANE_PROTOCOL">
<AU>Sena DF, Ramchand K</AU>
<TI>Neuroprotection for prevention and treatment of glaucoma in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2016-11-30 20:35:08 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-11-30 20:35:08 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006539"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sena-2010" MODIFIED="2012-12-05 17:40:44 +0000" MODIFIED_BY=" Iris Gordon" NAME="Sena 2010" TYPE="COCHRANE_REVIEW">
<AU>Sena DF, Ramchand K, Lindsley K</AU>
<TI>Neuroprotection for treatment of glaucoma in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-12-05 17:40:44 +0000" MODIFIED_BY=" Iris Gordon"><IDENTIFIER MODIFIED="2012-12-05 17:40:44 +0000" MODIFIED_BY=" Iris Gordon" TYPE="DOI" VALUE="10.1002/14651858.CD006539.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sena-2013" MODIFIED="2016-11-30 20:33:09 +0000" MODIFIED_BY="[Empty name]" NAME="Sena 2013" TYPE="COCHRANE_REVIEW">
<AU>Sena DF, Lindsley K</AU>
<TI>Neuroprotection for treatment of glaucoma in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2016-11-30 20:33:09 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-11-30 20:33:09 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006539.pub3"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-01-13 15:03:13 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-01-13 06:10:54 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2017-01-13 06:03:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-LoGTS-2011">
<CHAR_METHODS MODIFIED="2017-01-13 05:27:22 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B> parallel-group randomized controlled trial</P>
<P>
<B>Number randomized (total and per group):</B> 190 total participants randomized; number per group not reported</P>
<P>
<B>Number analyzed (total and per group):</B>
</P>
<P>
<B>Exclusions:</B> 12 total participants randomized; number per group not reported</P>
<P>
<B>Loss to follow-up: </B>at 1 year, 36/99 (36%) participants in brimonidine group and 8/79 (10%) participants in timolol group were lost to follow-up; at 4 years, 54/99 (55%) participants in brimonidine group and 23/79 (29%) participants in timolol group were lost to follow-up</P>
<P>
<B>Study</B> planned follow-up was 4 years</P>
<P>
<B>Sample size calculation:</B> 64 participants for 80% power to detect outcome differences between groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-13 05:28:37 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Country:</B> USA (13 clinical centers)</P>
<P>
<B>Age (mean ± standard deviation):</B> 64.9 ± 10.7 years</P>
<P>
<B>Gender:</B> women (n = 113; 59.5%); men (n = 77; 40.5%)</P>
<P>
<B>Inclusion criteria: </B>"Men and women, &#8805; 30 years of age, with previously diagnosed LPG. Untreated LPG with Goldmann applanation IOP &#8804; 21 mmHg on a diurnal (8 AM, 10 AM, 12 PM, 4 PM) curve before medication randomization."</P>
<P>
<B>Exclusion criteria: </B>"History of untreated IOP &gt; 21 mmHg, or a &gt; 4 mmHg difference in IOP between the eyes. Advanced visual field loss (mean deviation, &gt; 15 dB) or threat to fixation. Corrected visual acuity &lt; 20/40 in either eye. Pigmentary or exfoliative glaucoma. History of angle-closure or an occludable angle by gonioscopy. Prior filtration surgery or laser iridotomy. Cataract surgery with posterior chamber lens implant performed less than 1 year before enrollment. Argon laser trabeculoplasty performed less than 6 months previously or for an untreated IOP &gt; 21 mmHg. History or signs of inflammatory eye disease, ocular trauma, or potentially progressive retinal disease. History of allergy or intolerance to topical timolol, brimonidine, or to any components of these medications. Resting pulse rate &lt; 50 beats/minute. Severe, unstable, or uncontrolled cardiovascular, renal, or pulmonary disease. Women pregnant, nursing, or contemplating pregnancy."</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-13 06:00:09 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention 1:</B> bilateral treatment with topical brimonidine 0.2% twice daily</P>
<P>
<B>Intervention 2:</B> bilateral treatment with topical timolol 0.5% twice daily</P>
<P>
<B>General procedures for all participants: </B>topical ocular hypotensive medications were discontinued prior to study with appropriate washout periods; no other IOP-lowering agents were allowed during study period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-13 06:02:23 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome, as defined in baseline paper:</B> "Significant progression of the same two or more points, on the Humphrey glaucoma change probability maps or by Progressor linear regression analysis, in 3 consecutive (over an 8-month period) Humphrey 24-2 full threshold fields."</P>
<P>
<B>Primary outcome, as defined in results paper:</B> "The primary outcome measure was visual field progression in either eye as determined by pointwise linear regression analysis of all study visual fields with Progressor software (Medisoft Inc., Leeds, UK)."</P>
<P>
<B>Secondary outcome, as defined in results paper:</B> "A secondary outcome was visual field progression in either eye evaluated by Humphrey glaucoma change probability maps (GCPM)."</P>
<P>
<B>Other measurements taken at baseline and follow-up</B> <B>visits:</B> "patient reported ocular and systemic events; measurement of blood pressure, pulse, best-corrected visual acuity, and IOP; slit-lamp examination; and optic disc evaluation for cup-to-disc ratio and the presence or the absence of disc hemorrhage. Gonioscopy and stereoscopic optic disc photographs are performed at yearly intervals. Humphrey achromatic visual fields (full-threshold 24-2 program) are performed according to protocol guidelines at 4-month intervals after randomization." Measurements taken "every 4 months with visual fields and yearly optic disc photographs for a minimum of 4 years."</P>
<P>
<B>Unit of analysis:</B> individual (patient-based)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-13 06:03:01 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Study dates:</B> enrollment from June 1998 to August 2000</P>
<P>
<B>Funding source(s):</B> Allergan Inc. (Irvine, CA); Chicago Center for Vision Research (Chicago, IL)</P>
<P>
<B>Conflicts of interest:</B> none reported</P>
<P>
<B>Publication language:</B> English</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>Abbreviations</B>
</P>
<P>IOP: intraocular pressure<BR/>LPG: low-pressure glaucoma</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-01-13 15:03:13 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:17:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alm-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:17:40 +0000" MODIFIED_BY="[Empty name]">
<P>Not the population of interest: 5-year, multicenter, open-label safety study of adjunctive latanoprost therapy for glaucoma; was excluded because the people included in the study had either POAG or exfoliation glaucoma, and the results for both types were combined.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:20:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:20:59 +0000" MODIFIED_BY="[Empty name]">
<P>Not the population of interest: RCT evaluating whether the benefit of lowering IOP varies according to certain traits; was excluded because the outcome measured (the benefit of lowering IOP and how it varies according to certain traits) was not predefined as an outcome of interest of this review. Also, it was unclear whether the treatment was topical or oral.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:22:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Araie-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:22:03 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT of nipradilol versus timolol in people with NTG. Participants were followed for 3 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:22:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Araie-2011a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:22:16 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial: review of pressure-independent damaging factors of open angle glaucoma</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:22:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Araie-2011b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:22:20 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial: review of calcium channel blockers for glaucoma</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:22:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blumenthal-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:22:26 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial: review of methods to assess retinal nerve fiber layers for use in trials</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:22:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cantor-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:22:45 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial: review of brimonidine, however none of the studies reported met the inclusion criteria for this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:23:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cellini-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:23:32 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial: prospective case series of people with ocular hypertension treated with omega-3 polyunsaturated fatty acids for 3 months</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:23:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chader-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:23:45 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial: review of neurotrophic agents used in glaucoma</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:30:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Changhua-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:30:52 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: evaluation of the neuroprotective effect of <I>Erigeron breviscapus</I> (vant.) Hand. Mazz. (EBHM) on people with IOP-controlled glaucoma. Participants were followed for 6 months.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:33:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:33:24 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial: prospective case series of patients switched to unoprostone isopropyl ophthalmic solution (Rescula) after initial treatment with beta-blockers. Participants were followed for 1 year.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 15:03:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cho-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 14:55:52 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: evaluation of fixed combination of brimonidine 0.2%-timolol 0.5% in people with glaucoma. Participants were followed for up to 6 months.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-09 17:59:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CNTGS-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-09 17:59:12 +0000" MODIFIED_BY="[Empty name]">
<P>Not intervention of interest: included any medical and surgical treatment to lower IOP, and was not limited to the agents listed in the protocol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:36:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial: review of ocular hypotensive agents for the treatment of glaucoma and ocular hypertension</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:37:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cordeiro-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:37:00 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial: editorial discussing clinical trials for neuroprotection in glaucoma</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:37:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Costagliola-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:37:52 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT of palmitoylethanolamide versus no palmitoylethanolamide in people with NTG. Participants were followed for 6 months.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:38:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Danesh_x002d_Meyer-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:38:05 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial: review of preclinical (animal and cellular) studies for neuroprotection in glaucoma</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:38:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Drance-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:38:25 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: randomized, masked study of the effects of betaxolol, timolol, and pilocarpine on visual functions in people with OAG over a 24-month period</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:40:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EMGT-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:40:45 +0000" MODIFIED_BY="[Empty name]">
<P>Not intervention of interest: randomized comparison of the effect of laser trabeculoplasty plus topical betaxolol hydrochloride versus no initial treatment; was excluded because laser trabeculoplasty was not a predefined intervention for this review. Also, this review did not include exfoliation glaucoma.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:42:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eren-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:42:08 +0000" MODIFIED_BY="[Empty name]">
<P>Not intervention of interest: cross-over RCT of dorzolamide/timolol fixed combination compared with latanoprost/timolol fixed combination in people with OAG. Each treatment phase was 6 weeks, with a 6-week washout period.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:43:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Erichev-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:43:34 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: cross-over RCT of intravenous choline alphoscerate versus oral choline alphoscerate in participants with progressive glaucomatous optic neuropathy. Each treatment phase was 4 months.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:43:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evans-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:43:44 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT of timolol versus brimonidine in POAG. Measurements taken at baseline and 3 months.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:43:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frolov-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:43:56 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT of 1000 mg/day vs 500 mg/day intravenous citicoline for 10 days</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:44:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gandolfi-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:44:12 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT of brimonidine 0.2% twice daily vs argon laser trabeculoplasty. Follow-up was 18 months after randomization.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:44:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garcia_x002d_Medina-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:44:29 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: placebo-controlled RCT of oral antioxidant supplementation for POAG. Follow-up was 2 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:44:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ge-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:44:54 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial: review of preclinical (animal and cellular) studies for neuroprotection in glaucoma</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:45:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guo-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:45:29 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: cross-over RCT of <I>Ginkgo biloba</I> extract compared with placebo in people with NTG. Each treatment phase was 4 weeks, with an 8-week washout period.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:47:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harris-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:47:33 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT comparing the effect of selective (betaxolol) and non-selective (timolol) beta-adrenergic blocking drugs on flow velocities in orbital vessels in 13 people with NTG. Trial period consisted of a 1-month drug treatment double-masked cross-over design, with a 3-week washout before each drug was used.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:48:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harris-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:48:26 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT to determine how dorzolamide alters visual function and ocular blood flow in people with NTG. Trial period was 4 weeks.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:48:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoyng-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:48:35 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial: review of medical treatment for NTG</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:49:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iester-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:49:51 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT on short-term effects after switching or adding bimatoprost in people with POAG. Measurements taken at baseline, 1 h, 2 h, 1 week, 1 month, and 3 months.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-10 12:15:28 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Inan-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-10 12:15:28 +0000" MODIFIED_BY="Anupa Shah">
<P>Short-term trial: randomized, open-label, parallel study on the effects of latanoprost and brimonidine on blood flow velocity of retrobulbar vessels. Measurements taken at baseline and 3 months.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:50:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kass-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:50:52 +0000" MODIFIED_BY="[Empty name]">
<P>Not the population of interest: 5-year, randomized, double-masked study on whether treatment with topical timolol maleate was effective in preventing or delaying the onset of glaucomatous visual field loss in participants with ocular hypertension</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:51:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kjellgren-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:51:09 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT of latanoprost versus placebo given topically twice a day for 14 days in 20 people with NTG</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:51:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koseki-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:51:24 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT to study the effect of oral brovincamine on further deterioration of visual field in people with NTG over a 2-year period</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:51:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:51:36 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT of latanoprost versus brimonidine in people with NTG. Trial period was 4 weeks.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:52:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ma-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:52:09 +0000" MODIFIED_BY="[Empty name]">
<P>Not intervention of interest: RCT of pneumatic trabeculoplasty compared with latanoprost in people with POAG. Measurements were taken up to 6 months after treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:52:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mastropasqua-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:52:30 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT on the effect of acute administration of 1% apraclonidine on visual field parameters. Measurements were taken at baseline and 2 h after administration of drops.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:52:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCarty-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:52:58 +0000" MODIFIED_BY="[Empty name]">
<P>Not the population of interest: RCT evaluating the acute neuroprotective qualities of brimonidine during LASIK; people with glaucoma were excluded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:53:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Donoghue-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:53:22 +0000" MODIFIED_BY="[Empty name]">
<P>Not the population of interest: RCT of latanoprost versus dorzolamide; excluded because the included participants had either POAG or ocular hypertension. Trial period was 3 months.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:54:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Park-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:54:09 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT of <I>Ginkgo biloba </I>extract on ocular blood flow in people with NTG. Follow-up was 2 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:54:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pfeiffer-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:54:27 +0000" MODIFIED_BY="[Empty name]">
<P>Not the population of interest: RCT of latanoprost and timolol; excluded because the included participants had either POAG or ocular hypertension. Trial period was 6 months.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:54:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roberti-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:54:46 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT of topical citicoline plus hypotensive therapy compared with hypotensive therapy alone in people with OAG. Trial period was 3 months.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:55:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Robin-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:55:54 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT of 1% topical apraclonidine in reducing IOP following combined cataract surgery in people with POAG. Measurements were taken at baseline, 24 h, 1 week, 2 weeks, and 4 weeks after surgery.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:56:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rulo-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:56:23 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT evaluating the IOP-reducing potential and side effects of latanoprost in people with NTG. Trial period was 3 weeks for each treatment (50 &#956;g/mL latanoprost once daily, 15 &#956;g/mL latanoprost twice daily, and placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:57:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sari-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:57:21 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT of <I>Ginkgo biloba</I> extract compared with placebo in people with POAG. Trial period was 6 months.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 06:58:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sawada-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 06:58:01 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT of brovincamine fumarate versus placebo for NTG. Participants were followed for 2.5 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 09:18:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 09:18:49 +0000" MODIFIED_BY="[Empty name]">
<P>Short-term trial: RCT evaluating the protective effect of yiyanming on the optic nerve of people with POAG and controlled IOP. Participants were followed for 12 weeks.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-13 07:01:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-13 07:01:10 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized trial: cohort of patients with acute angle-closure glaucoma given nerve growth factor gel or saline after trabeculectomy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>Abbreviations</B>
</P>
<P>IOP: intraocular pressure<BR/>LASIK: laser-assisted in-situ keratomileusis<BR/>NTG: normal-tension glaucoma<BR/>OAG: open angle glaucoma<BR/>POAG: primary open angle glaucoma<BR/>RCT: randomized controlled trial<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2017-01-13 07:06:59 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2017-01-13 07:04:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00141882">
<CHAR_METHODS MODIFIED="2017-01-13 07:04:04 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled, parallel-assignment study (phase III trial).</P>
<P>Enrollment: 1100 participants</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-13 07:02:16 +0000" MODIFIED_BY="[Empty name]">
<P>Adults (18 to 80 years) with open angle glaucoma</P>
<P>Inclusion criteria: glaucoma damage on examination of the visual field and optic disc; good visual acuity (with glasses if needed)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-13 07:02:27 +0000" MODIFIED_BY="[Empty name]">
<P>3 arms: high-dose memantine; low-dose memantine; placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-13 07:02:37 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: progression of glaucoma</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-13 07:02:56 +0000" MODIFIED_BY="[Empty name]">
<P>Study sponsored by Allergan Inc.</P>
<P>Study was completed as of 18 December 2007.</P>
<P>Study information collected from trial registration and press release by Allergan Inc.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-01-13 07:05:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00168350">
<CHAR_METHODS MODIFIED="2017-01-13 07:04:28 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled, parallel-assignment study (phase III trial).</P>
<P>Enrollment: 1100 participants</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-13 07:04:44 +0000" MODIFIED_BY="[Empty name]">
<P>Adults (18 to 80 years) with open angle glaucoma</P>
<P>Inclusion criteria: glaucoma damage on examination of the visual field and optic disc; good visual acuity (with glasses if needed)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-01-13 07:04:50 +0000" MODIFIED_BY="[Empty name]">
<P>3 arms: high-dose memantine; low-dose memantine; placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-13 07:04:55 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: progression of glaucoma</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-13 07:05:31 +0000" MODIFIED_BY="[Empty name]">
<P>Study sponsored by Allergan Inc.</P>
<P>Study was completed as of 18 December 2007.</P>
<P>Study information collected from trial registration and press release by Allergan Inc.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>It is not clear which trial numbers correspond to the first study completed and which correspond to the second study completed. Press release only mentions that the results of the second phase III trial differed from the first phase III trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-12-02 19:38:13 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-01-13 06:10:54 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-01-10 12:15:01 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-10 12:15:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LoGTS-2011">
<DESCRIPTION>
<P>"Participants were assigned to 1 of 2 treatment groups, brimonidine tartrate 0.2% or timolol maleate 0.5% (both medications used throughout the study), according to a computer-generated randomization list stratified by center."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-01-10 12:15:06 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-10 12:15:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LoGTS-2011">
<DESCRIPTION>
<P>"The randomization assignment list is maintained and masked study medications are provided directly to the clinical centers by Fountain Valley Pharmacy (Fountain Valley, CA). Optic disc, visual field, and coordinating centers are masked from each other. Data on treatment effects and the randomization code are not provided during the course of the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2012-07-20 20:53:13 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Masking of participants and personnel (performance bias)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-19 21:39:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LoGTS-2011">
<DESCRIPTION>
<P>"Full masking of patients, physicians, technicians, and the reading center for visual fields and optic disc photographs."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2012-07-20 20:53:13 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Masking of outcome assessment (detection bias)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-19 21:39:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LoGTS-2011">
<DESCRIPTION>
<P>"Full masking of patients, physicians, technicians, and the reading center for visual fields and optic disc photographs."</P>
<P>"Data Center for masked computer analysis of the visual fields."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-07-19 21:36:21 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-07-19 21:36:21 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-07-19 21:36:21 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-01-13 06:10:07 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>Rates of loss to follow-up</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Exclusion of participants</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.03" NO="3">
<NAME>Handling of missing data</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-10 12:15:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-LoGTS-2011">
<DESCRIPTION>
<P>"12 randomized patients were subsequently excluded (10 from withdraw of a study site, 1 withdrew consent, and 1 did not meet entry criteria)."</P>
<P>"End points requiring withdrawal from the study include the following: (1) treated IOP of more than 21 mmHg that is repeatable within 1 month; (2) visual field progression; (3) development of allergy or intolerance to the study medication; (4) clinical decision by the treating ophthalmologist that it is unsafe for the patient to continue in the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2017-01-13 06:10:07 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-LoGTS-2011">
<DESCRIPTION>
<P>"Statistically more subjects assigned to brimonidine (36/99, 36.4%) dropped out prior to the year-1 examination than assigned to timolol (8/79, 10.1%) (<I>P </I>&lt; .001). The most common reason for discontinuation before the year-1 examination was localized ocular allergy that necessitated discontinuing the study medication in 20 of the 99 (20.2%) brimonidine and 3 of the 79 (3.8%) timolol subjects (<I>P </I>&lt; .001)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2012-07-19 21:41:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-LoGTS-2011">
<DESCRIPTION>
<P>"Collection of data from discontinued patients ceased at their final study visit. Data up to this point were included in the analysis, but discontinued patients were no longer followed as part of the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-01-13 06:10:54 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-13 06:10:54 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-LoGTS-2011">
<DESCRIPTION>
<P>Definitions of primary and secondary outcomes differed between baseline paper and results paper. Results that were measured for some outcomes were not reported (i.e. cup-disc ratio, visual acuity).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-01-09 17:50:21 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-09 17:50:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-LoGTS-2011">
<DESCRIPTION>
<P>"Publication of this article was supported by an unrestricted grant to the Low-Pressure Glaucoma Study Group from Allergan, Inc, Irvine, California; the Chicago Center for Vision Research, Chicago, Illinois; and an unrestricted grant from Research to Prevent Blindness, Inc, New York, New York (Northwestern University). Study medications were provided by Allergan, Inc. Funding organizations had no role in the design and conduct of the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-01-16 17:37:01 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-01-16 17:37:01 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2017-01-16 17:37:01 +0000" MODIFIED_BY="[Empty name]">Neuroprotection compared with control for glaucoma</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Neuroprotection compared with control for glaucoma</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Population: </B>adults with open angle glaucoma</P>
<P>
<B>Settings: </B>ophthalmology clinics</P>
<P>
<B>Intervention: </B>brimonidine 0.2%</P>
<P>
<B>Comparison: </B>timolol 0.5%</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes*</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks** (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Certainty of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control (timolol)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Neuroprotection (brimonidine)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Visual field: the proportion of participants with progression of visual field loss at 4 years' follow-up</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>321 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>113 per 1000</B>
<BR/>(45 to 276)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.35</B> (0.14 to 0.86)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>101<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1,2</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Visual acuity: the proportion of participants with loss of visual acuity at 4 years' follow-up</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Trial investigators reported visual acuity changes within treatment groups; no between-group data reported.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intraocular pressure: mean IOP at 4 years' follow-up</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IOP was 14.0 mmHg in the timolol group.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean IOP in the brimonidine group was <B>0.20 mmHg higher</B>
<BR/>(0.73 mmHg lower to 1.13 mmHg higher).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>MD 0.20</B> (-0.73 to 1.13)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>91<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1,2</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Among participants with visual field loss at 4 years, the RR for IOP reduction of 20% or greater was 1.15 (95% CI 0.49 to 2.70) when comparing 9 brimonidine participants with 31 timolol participants (very low certainty).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Vertical cup-disc ratio: the proportion of participants with asymmetrical vertical cup-disc ratio greater than 0.3 at 4 years' follow-up</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No vertical cup-disc ratio outcome was reported by the study.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adverse effects: ocular allergy to the study medication requiring discontinuation up to 4 years' follow-up</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>38 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>202 per 1000</B>
<BR/>(62 to 655)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 5.32</B> (1.64 to 17.26)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>178<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1,2</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 participants, 5 in the brimonidine group and 1 in the timolol group, died during the study due to causes unrelated to the study treatments.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Quality of life measures</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No quality of life outcome was reported by the study.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Economic data</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No economic outcome was reported by the study.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The primary follow-up time point for this review was 5 years, however data were only available at 4 years.<BR/>**The basis for the <B>assumed risk</B> is risk in the control group. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the control group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>MD:</B> mean difference; <B>IOP:</B> intraocular pressure; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High certainty:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate certainty:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low certainty:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low certainty:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Downgraded for attrition bias (-2): data missing for 55% of participants in brimonidine group versus 29% of participants in timolol group.<BR/>
<SUP>2</SUP>Downgraded for selective outcome reporting (-1): definitions of primary and secondary outcomes differed between baseline paper and results paper; results for some outcomes that were measured were not reported (i.e. cup-disc ratio, visual acuity).</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-07-25 20:18:11 +0100" MODIFIED_BY="[Empty name]"/>
<FIGURES MODIFIED="2017-01-13 08:39:05 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-01-13 08:39:05 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAnoAAAGGCAYAAADsEizzAABCEUlEQVR42u2dD4SV2f/Hv6y1VlYi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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-12-13 10:45:56 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-01-15 16:19:12 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-05-23 14:47:23 +0100" MODIFIED_BY="Anupa Shah">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-01-15 16:19:12 +0000" MODIFIED_BY="[Empty name]">
<P>#1 MeSH descriptor Glaucoma<BR/>#2 glaucoma*<BR/>#3 (#1 OR #2)<BR/>#4 MeSH descriptor Neuroprotective Agents<BR/>#5 neuroprotect*<BR/>#6 MeSH descriptor Retinal Ganglion Cells<BR/>#7 ganglion near cell*<BR/>#8 retina* near cell*<BR/>#9 RGC<BR/>#10 MeSH descriptor Optic Nerve Diseases<BR/>#11 optic near neuropath*<BR/>#12 MeSH descriptor Memantine <BR/>#13 memantine<BR/>#14 (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13)<BR/>#15 (#3 AND #14)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-12-13 10:42:04 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2016-12-13 10:41:25 +0000" MODIFIED_BY="[Empty name]">MEDLINE Ovid search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-12-13 10:42:04 +0000" MODIFIED_BY="[Empty name]">
<P>1. randomized controlled trial.pt.<BR/>2. (randomized or randomised).ab,ti.<BR/>3. placebo.ab,ti.<BR/>4. dt.fs.<BR/>5. randomly.ab,ti.<BR/>6. trial.ab,ti.<BR/>7. groups.ab,ti.<BR/>8. or/1-7<BR/>9. exp animals/<BR/>10. exp humans/<BR/>11. 9 not (9 and 10)<BR/>12. 8 not 11<BR/>13. exp glaucoma/<BR/>14. glaucoma$.tw.<BR/>15. or/13-14<BR/>16. exp neuroprotective agents/<BR/>17. neuroprotect$.tw.<BR/>18. exp retinal ganglion cells/<BR/>19. (ganglion adj2 cell$).tw.<BR/>20. (retina$ adj2 cell$).tw.<BR/>21. RGC.tw.<BR/>22. exp optic nerve disease/<BR/>23. (optic adj2 neuropath$).tw.<BR/>24. Memantine/<BR/>25. memantine.tw.<BR/>26. or/16-25<BR/>27. 15 and 26<BR/>28. 12 and 27</P>
<P>The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by <LINK REF="REF-Glanville-2006" TYPE="REFERENCE">Glanville 2006</LINK>.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-12-13 10:41:48 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2016-12-13 10:41:48 +0000" MODIFIED_BY="[Empty name]">Embase Ovid search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-01-15 13:31:34 +0000" MODIFIED_BY="[Empty name]">
<P>1. exp randomized controlled trial/<BR/>2. exp randomization/<BR/>3. exp double blind procedure/<BR/>4. exp single blind procedure/<BR/>5. random$.tw.<BR/>6. or/1-5<BR/>7. (animal or animal experiment).sh.<BR/>8. human.sh.<BR/>9. 7 and 8<BR/>10. 7 not 9<BR/>11. 6 not 10<BR/>12. exp clinical trial/<BR/>13. (clin$ adj3 trial$).tw.<BR/>14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.<BR/>15. exp placebo/<BR/>16. placebo$.tw.<BR/>17. random$.tw.<BR/>18. exp experimental design/<BR/>19. exp crossover procedure/<BR/>20. exp control group/<BR/>21. exp latin square design/<BR/>22. or/12-21<BR/>23. 22 not 10<BR/>24. 23 not 11<BR/>25. exp comparative study/<BR/>26. exp evaluation/<BR/>27. exp prospective study/<BR/>28. (control$ or prospectiv$ or volunteer$).tw.<BR/>29. or/25-28<BR/>30. 29 not 10<BR/>31. 30 not (11 or 23)<BR/>32. 11 or 24 or 31<BR/>33. exp glaucoma/<BR/>34. glaucoma$.tw.<BR/>35. or/33-34<BR/>36. exp neuroprotective agent/<BR/>37. neuroprotect$.tw.<BR/>38. exp retinal ganglion cell/<BR/>39. (ganglion adj2 cell$).tw.<BR/>40. (retina$ adj2 cell$).tw.<BR/>41. RGC.tw.<BR/>42. exp optic nerve disease/<BR/>43. (optic adj2 neuropath$).tw.<BR/>44. Memantine/<BR/>45. memantine.tw.<BR/>46. or/36-45<BR/>47. 35 and 46<BR/>48. 32 and 47<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2010-01-15 16:22:40 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2008-05-23 14:47:57 +0100" MODIFIED_BY="Anupa Shah">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-01-15 16:22:40 +0000" MODIFIED_BY="[Empty name]">
<P>glaucoma$ and neuroprotect$ or memantine</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-12-13 10:44:48 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2016-12-13 10:41:08 +0000" MODIFIED_BY="[Empty name]">ISRCTN search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-12-13 10:44:48 +0000" MODIFIED_BY="[Empty name]">
<P>glaucoma AND (neuroprotection OR memantine)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2016-12-13 10:45:56 +0000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2010-01-15 13:47:24 +0000" MODIFIED_BY="[Empty name]">ClinicalTrials.gov search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-12-13 10:45:56 +0000" MODIFIED_BY="[Empty name]">
<P>glaucoma AND (neuroprotection OR memantine)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2012-12-05 11:32:34 +0000" MODIFIED_BY=" Iris Gordon" NO="7">
<TITLE MODIFIED="2012-12-05 11:23:02 +0000" MODIFIED_BY=" Iris Gordon">ICTRP search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-12-05 11:32:34 +0000" MODIFIED_BY=" Iris Gordon">
<P>glaucoma = Condition AND neuroprotection or memantine = Intervention</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 study included in qualitative synthesis (no meta-analysis)&lt;/p&gt;" WIDTH="137">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 included study in previous version of the review (from search as of 16 October 2012)&lt;/p&gt;" WIDTH="151"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;11 full-text reports assessed for eligibility&lt;/p&gt;" WIDTH="199">
<FLOWCHARTBOX TEXT="&lt;p&gt;1294 records screened&lt;/p&gt;" WIDTH="197">
<FLOWCHARTBOX TEXT="&lt;p&gt;1294 unique records identified through searching electronic databases (16 October 2012 to 16 August 2016)&lt;/p&gt;" WIDTH="199"/>
<OUT TEXT="&lt;p&gt;1283 records excluded&lt;/p&gt;" WIDTH="164"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;11 reports from 8 studies excluded, with reasons&lt;/p&gt;" WIDTH="163"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>